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ABSTRACT 
The Association of Markers of Endothelial Dysfunction and Incident 
Diabetes Mellitus, Hypertension, Chronic Kidney Disease and Cardiovascular Mortality 
 
Loretta R Cain 
 
In recent years several mechanistic animal studies have proposed new insights, including 
the role of endothelial dysfunction, in the pathogenesis of common cardiometabolic disorders 
such as diabetes mellitus, hypertension, chronic kidney disease (CKD) and cardiovascular 
disease (CVD).  However, few studies in humans have followed up these emerging leads from 
animal models. Because traditional risk factors have been shown not to completely explain all 
the observed risk of cardiometabolic outcomes in the general population, there is a need to 
examine novel mechanisms such as endothelial dysfunction in population-based studies, so as to 
identify new ways of preventing and/or treating these diseases. In this context, we examined the 
novel hypothesis that higher serum levels of markers of endothelial dysfunction, including 
soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion 
molecule-1 (sICAM-1), are positively associated with the risk of developing  diabetes mellitus, 
hypertension, CKD and cardiovascular mortality in four separate studies. We measured sVCAM-
1 and sICAM-1 levels from stored serum in a random sample (n=1793) of baseline participants 
from the Beaver Dam Eye Study, a population-based, longitudinal cohort study of n=4926 
subjects (55% women), aged ≥43 years from Beaver Dam, Wisconsin. The main outcomes of 
interest were 15 year incidence of diabetes mellitus, hypertension, CKD and CVD mortality 
occurring between the baseline examination at 1988-90 to the end of mortality follow-up at Dec 
31, 2002.  During the stated follow-up period, 156 subjects developed diabetes mellitus, 257 
subjects developed hypertension, 269 subjects developed CKD and 212 subjects died of 
cardiovascular causes. We found that serum levels of sVCAM-1 and SICAM-1 are positively 
related to diabetes mellitus in men only (hazards ratio [HR] (95% confidence interval [CI]) =2.29 
[1.18-4.44] for sVCAM-1 in men), and with hypertension (HR=2.14 [1.42-3.23] for sVCAM-1) 
and CVD mortality (HR= 1.79 [1.17-2.76] for sICAM-1) in both men and women. In contrast, 
markers of endothelial dysfunction were not found to be related to CKD.  In conclusion, we have 
shown that serum markers of endothelial dysfunction are associated with higher risk of 
developing diabetes mellitus, hypertension and CVD mortality, but not with CKD. 
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Introduction 
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1.1 CARDIOVASCULAR DISEASE, DIABETES, HYPERTENSION, CHRONIC 
KIDNEY DISEASE AND THE NEED FOR NOVEL MARKERS 
 According to the Centers for Disease Control and Prevention (CDC), 2.4 million deaths 
occurred in the United States, with cardiovascular disease (CVD) being the number one cause of 
death in the United States.1  Risk factors for CVD mortality include age,2 low physical activity,3 
diabetes mellitus,4 hypertension,5 coronary heart disease,4 and CKD.6  However, these traditional 
risk factors do not explain all the CVD risk in the general population and therefore there is a 
need to identify novel risk factors. In this context, mechanistic animal studies have proposed new 
molecular insights into the pathogenesis of CVD, such as the role of inflammation, and 
endothelial dysfunction.7 There is a need to examine these novel pathogenetic mechanisms in 
population-based studies with an aim of identifying novel predictive markers and also to advance 
our understanding of CVD pathogenesis in humans. 
Diabetes mellitus is a known risk factor for CVD,8 and according to the 2007 National 
Diabetes Fact Sheet by CDC, 23.6 million and adults in the United States (7.8% of the 
population) have diabetes.9  Known risk factors for diabetes include increasing age,10 higher 
body mass index (BMI),11 hypertension,12 central obesity,13 insulin resistance7 and dietary 
factors.14 Emerging evidence suggest that endothelial dysfunction may be a causative factor in 
the development of diabetes mellitus also.7 
Similarly, hypertension is a known risk factor for cardiovascular disease, including 
myocardial infarction, heart failure and stroke.15 A recent study comparing two consecutive 
national surveys reported an increase in the prevalence of hypertension from 23.9% in 1988-
1994 to 29.0% in 2007-2008. 16 Risk factors for hypertension include a family history of 
hypertension17, age18-20, gender21,22, physical inactivity23-25, high-salt intake26-28, 
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overweight/obesity20,29,30, alcohol20, smoking30,31 and diabetes mellitus15,19,32 However, these 
traditional risk factors may not account for all the observed risk of hypertension in the general 
population.33  In this context, based on predominantly data from animal studies,34 endothelial 
dysfunction is now being proposed as a novel mechanism that may be involved in the 
development of hypertension. 
Chronic kidney disease (CKD) is recognized as a strong risk factor for incident CVD35,  
including coronary artery disease and stroke, and it also independently predicts CVD mortality.36 
Identifying risk factors for CKD are therefore important in preventing CVD.35 A recent study 
comparing two consecutive national surveys reported an increase in the prevalence of CKD 
between 1988-1994 and 1999-2004 suggesting it to be a growing public health problem.37 
Diabetes mellitus 38,39 and hypertension 39-44 have been consistently shown to be important risk 
factors in the development of kidney disease. Studies have shown that several of the known 
cardiovascular risk factors are also related to the development of CKD, including advancing 
age,38,39,45,46 male sex,39-44 obesity,39-44,47 smoking,39,44,48 high triglycerides,49 low high-density 
lipoprotein (HDL) cholesterol,39,49,50 and a mild reduction in GFR at baseline.39 However, these 
traditional risk factors do not account for all the observed CKD risk in the general 
population.39,51,52 Therefore studies are needed to examine the role of new predictors in the 
development of CKD, including markers of endothelial dysfunction.  
   
1.2 MARKERS OF ENDOTHELIAL DYSFUNCTION 
The vascular endothelium is involved in a variety of key processes important to human 
health and disease, including control of coagulation,53 fibrinolysis.53,54 vascular tone53,55 and 
growth,55 immune response53,55 and oxidative stress.54,56 Endothelial dysfunction has been found 
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to be closely related to insulin resistance,7,57 elevated levels of inflammatory markers,7,58 
impaired function of lipoprotein lipase (contributing to high triglycerides and low HDL 
cholesterol levels,7,58 impaired nitric oxide release58 and endothelium dependent vasodilation.58   
Studies suggest that endothelial dysfunction is associated with risk factors and processes 
associated with diabetes mellitus, such as hyperglycemia,59 inflammation,59 and insulin 
resistance.7,57  One of the well-known vasodilators produced in the endothelium is nitric oxide 
(NO) whose production is decreased due to endothelial dysfunction, 60 resulting from reduced 
activity of endothelial NO (eNOS). Early stages of endothelial dysfunction are related to 
increased production of reactive oxygen species (ROS) which in turn can cause more damage to 
endothelial and vascular function. 61 ROS are now considered to be a major risk factor in the 
development of insulin resistance, diabetes mellitus, hypertension, and CVD.62  
Endothelial dysfunction may cause hypertension by impairing the vasodilator mechanism 
of NO (which is also called endothelium-derived relaxing factor), subsequently causing elevated 
blood pressure.63 Endothelial dysfunction may also be related to other mechanisms involved in 
the development of hypertension, including insulin resistance64, systemic inflammation65 and 
hyperuricemia.66   
Endothelial dysfunction is present in end-stage renal disease.67,68 Biomarkers of 
endothelial dysfunction, including circulating adhesion molecules VCAM-1, ICAM-1, and E-
selectin are shown to be elevated even in less advanced stages of kidney disease.67,69,70 
Endothelin-1 (ET-1), an endothelium-derived growth factor, of both renal mesangial and extra-
renal vascular origin and its interaction with angiotensin-II are implicated in the progression of 
renal disease.71 For example, Koobi et al.72 showed that Angiotensin II type 1 (AT1) receptor 
blockade in nephrectomized rats significantly reduced the vasoconstriction response in relation 
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to Endothelin-1 administration.  Angiotensin-II, a central molecule in the initiation and 
progression of chronic renal disease49,73 is closely related to endothelial function and 
inflammation74 and treatment with angiotensin converting enzyme inhibitors have been shown to 
lower circulating biomarker levels of inflammation  and endothelial dysfunction75. These 
findings suggest that endothelial dysfunction may precede and can predict the development of 
CKD.  
Animal studies show that endothelial dysfunction may have a causative role in the 
development of cardiovascular disease.76 The intact, healthy endothelium secretes various 
cardio-protective substances including nitric oxide, which diffuses to surrounding tissues and 
cells, relaxing smooth-muscle cells and preventing platelet adhesion and aggregation, preventing 
expression of adhesion molecules, leukocyte adhesion and migration into the arterial wall and 
arterial smooth muscle cell proliferation77.  Conversely, early stages of endothelial dysfunction is 
characterized by increased formation of reactive oxygen species and increased expression of 
adhesion molecules such as sVCAM-1 and sICAM-1, which can react with NO forming 
peroxynitrate78, reducing NO bioavailability, which over the long run may be involved in 
increased risk of cardiovascular disease79. 
Because most methods of assessing endothelial dysfunction are invasive and are not 
suitable for large-scaled epidemiological studies,80 circulating levels of cellular adhesion 
molecules such as such as intercellular adhesion molecule 1 (ICAM-1), and vascular cell 
adhesion molecule 1 (VCAM-1)  are highly specific and valid markers of atherosclerosis–related 
endothelial dysfunction and have been used extensively in epidemiologic studies that utilized 
stored biospecimen 81,82 
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1.3 GAPS IN THE LITERATURE 
 
The few previous studies exploring the relationship between endothelial dysfunction and 
diabetes mellitus have reported contrasting relationships by gender, with some studies finding an 
association only in men83,84 and others in women.81 Therefore the relationship between 
endothelial dysfunction and diabetes mellitus by gender remains unclear.  In the current project, 
we will examine this association using serum markers of endothelial dysfunction, including 
sVCAM-1 and sICAM-1 in the Beaver Dam Eye Study, a large population-based cohort from 
Wisconsin which included men and women in approximately equal number. 
 Previous studies exploring the relationship between endothelial dysfunction and 
hypertension have found positive relationships in specialized populations such as pregnant 
women,85 subjects with type 1 diabetes,86 and those with obstructive sleep apnea-hypopnea 
syndrome.87 In the general population, only one previous cross-sectional study from China have 
examined this association.88 Even though they reported a positive association between serum 
sVCAM-1 and sICAM-1 levels and prevalent hypertension, due to the cross-sectional nature of 
the study, the authors could not clarify whether adhesion molecules were elevated prior to 
hypertension development or not. Therefore, a longitudinal cohort study exploring the 
relationship between endothelial dysfunction in the general population is needed.  In this context, 
we will prospectively examine this association using markers of endothelial dysfunction in the 
Beaver Dam Eye Study, a large, population-based, longitudinal cohort study from Wisconsin. 
 Previous cross-sectional studies exploring the relationship between endothelial 
dysfunction and CKD found positive associations.67,69,70  However, endothelial function markers 
are elevated as a consequence of CKD and dialysis.89,90 Therefore, a longitudinal study is 
necessary to determine whether or not endothelial dysfunction preceded CKD onset.  In the 
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current project, we will measure serum markers of endothelial dysfunction, including sVCAM-1 
and sICAM-1, from stored serum specimens at the baseline examination and examine its 
relationship to the risk of developing CKD over a 15 year follow-up period. 
 Previous studies have reported  associations between markers of endothelial dysfunction 
and cardiovascular mortality in ill populations, including those with kidney disease91, heart 
failure92 and arthritis93.  However, to our knowledge, no previous study has examined the 
association between markers of endothelial dysfunction and cardiovascular mortality in the 
general population. Therefore, we will use markers of endothelial dysfunction to explore 
cardiovascular mortality in a non-clinical population. 
 
1.4 SPECIFIC AIMS 
The primary objectives of the current dissertation project are to determine the relations of 
biomarkers of endothelial dysfunction to the long-term development of diabetes, hypertension, 
chronic kidney disease and cardiovascular mortality in the general population. The proposal 
takes advantage of the data on exposures and outcomes, including mortality, gathered over the 
last 15 years, from a population-based cohort in Beaver Dam, Wisconsin. In the Beaver Dam Eye 
Study (BEDS), we have data on glucose, glycosolated hemoglobin, and insulin injection use, 
blood pressure and serum creatinine measured at the baseline, 5-year, 10-year and 15-year 
follow-up examinations and mortality data which will enable us to define our primary outcomes, 
diabetes, hypertension, CKD, cardiovascular (CVD) mortality and all-cause mortality. We also 
have markers of endothelial dysfunction, including sVCAM-1 and sICAM-1 levels already 
measured from the baseline blood samples of the cohort as part of a previous ancillary study. Our 
study provides a unique opportunity to assess the temporal associations between new risk factors, 
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such as markers of endothelial dysfunction, and the development of diabetes, hypertension, CKD 
and mortality over a period of 15 years.   
 The specific aims of the current study are to determine the relation between biomarkers 
of endothelial dysfunction (intercellular adhesion molecule 1 [ICAM-1] and vascular cell 
adhesion molecule 1 [VCAM-1]) and the risk of developing  
 
1) diabetes mellitus;  
2) hypertension;  
3) CKD; and  
4) CVD mortality over a 15-year follow-up period. 
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Chapter 2  
 
 
Manuscript 1: The Association of Markers of Endothelial 
Dysfunction and Incident Diabetes 
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2.1 INTRODUCTION 
Endothelial dysfunction is a key pathophysiological process involved in the development of 
cardiovascular disease.94 Endothelial dysfunction has also been shown to be related to insulin 
resistance95, hyperglycemia59  and inflammation59 and therefore may have a role in the 
development of diabetes mellitus. Also, in subjects with diabetes, endothelial dysfunction has 
been reported to be predictive of subsequent complications, including nephropathy, retinopathy, 
and cardiovascular disease.96  Soluble adhesion molecules, including serum levels of vascular 
cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule -1 (sICAM-1) have 
been used as markers of endothelial dysfunction in epidemiological studies.97  However, few 
epidemiological studies have examined the relationship between soluble adhesion molecules and 
incident diabetes and the results have not been consistent, as some studies reported a positive 
association98-100  while others did not.84,101 Therefore, the independent relationship between 
sVCAM-1 and sICAM-1 and incident diabetes in the general population remains unclear. 
Therefore, we examined serum levels of sVCAM-1 and sICAM-1 in relationship to incident 
diabetes in a population-based sample of adults from Wisconsin. 
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2.2 METHODS 
 
2.2.1Population 
The current study is based on date from the Beaver Dam Eye study, a population-based 
cohort study in Wisconsin originally aimed at studying age-related eye diseases. The methods 
used to identify and describe the Beaver Dam population have appeared in previous 
reports.102,103In brief, a private census of the population of Beaver Dam, Wisconsin, was 
performed from September 1987 to May 1988 to identify all residents in the city or township of 
Beaver Dam who were 43-84 years of age. Of the 5,924 eligible individuals (98% Caucasians), 
4,926 (83.1%) participated in the baseline examination between March 1, 1988 and September 
14, 1990. Comparisons between participants and nonparticipants at the time of the baseline 
examination have appeared elsewhere.103 
The baseline examination was followed by a 5-year follow-up examination from 1993 to 
1995, a 10-year follow-up examination from 1998-2000, and a 15-year follow-up examination 
from 2003-2005. Written informed consent was obtained from each subject at each examination. 
The study was approved by the Human Subjects Committee of the University of Wisconsin 
School of Medicine and Public Health, Madison, WI. Levels of sVCAM-1 and sICAM-1 were 
measured in stored frozen serum on a random sample of the baseline cohort (n=1793) as part of 
an ancillary study examining risk factors for kidney disease.  
For the longitudinal analyses with sVCAM-1 and sICAM-1 as the main exposure, out of 
1793 individuals with available sICAM-1 and sVCAM-1 measurements who participated in the 
baseline and at least one follow-up examination, we excluded subjects with diabetes mellitus at 
baseline (n=84), missing information on covariates included in the multivariable model (n=326) 
and those who had a history of cardiovascular disease (n=264). This resulted in n=1119 diabetes-
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free individuals with biomarker complete covariate information to form the at-risk study 
population, among whom n=156 developed incident diabetes over the 15-year follow-up period.  
 
2.2.2 Exposure ascertainment 
The baseline and follow-up examinations included measurement of weight, height, 
systolic and diastolic blood pressure by trained observers and administering a standardized 
questionnaire that collected information regarding participants’ demographic characteristics, 
details regarding cigarette smoking, alcohol intake, medical histories and medications taken, 
including physician-diagnosed diabetes, hypertension or cardiovascular disease (CVD). Non-
fasting blood specimens were obtained for measurement of plasma glucose, glycosylated 
hemoglobin, serum total cholesterol and high density lipoprotein (HDL) cholesterol.  
Age was defined as the participants’ age at the time of the baseline examination. 
Education was categorized as less than high school, high school, or beyond high school. Body 
mass index (BMI) was defined as participants’ weight in kilograms divided by their height in 
meters squared. Hypertension was defined as a systolic blood pressure of 140 mmHg or higher, 
and/or a diastolic blood pressure 90 mmHg or higher, and/or the combination of self-reported 
hypertension diagnosis by a physician and use of antihypertensive medications.  
At cohort examinations, blood samples were collected in three 10-mL liquid EDTA blood 
tubes, placed on ice packs, stored in Styrofoam containers until they were centrifuged and 
aliquoted for storage in freezers at –800C until the time of laboratory analysis. Quality control 
samples were routinely frozen with study participant samples. Baseline frozen plasma samples 
were randomly ordered (to further reduce systematic bias and inter assay variation) and thawed 
and batch-analyzed for markers of endothelial function (sICAM-1, sVCAM-1). 
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sICAM-1 (soluble intercellular adhesion molecule-1) was measured in plasma using the 
quantitative sandwich enzyme technique of the enzyme-linked immunosorbent assay (ELISA) 
Parameter kit from R & D Systems (Minneapolis, MN).  The intensity of the color was measured 
on a SpectraMax spectrophotometer (Molecular Devices, Sunnyvale, California).  The inter-
assay CV range was 6.0-10.1% for the plasma assay.  
sVCAM-1 (soluble vascular cell adhesion molecule-1) was measured in plasma or serum 
using the quantitative sandwich enzyme technique of the enzyme-linked immunosorbent assay 
(ELISA) Parameter kit from R & D Systems (Minneapolis, MN).  The intensity of the color was 
measured on a SpectraMax spectrophotometer (Molecular Devices, Sunnyvale, California).  The 
inter-assay CV range was 8.9-10.2% for the plasma assay. 
 
2.2.3 Outcome of Interest: Diabetes Mellitus 
Persons were defined as having diabetes mellitus if were treated with insulin, oral 
hypoglycemic agents, or were newly classified as having diabetes based on the glycosylated 
hemoglobin value that was ≥ 6.5%, consistent with recent American Diabetes Association 
guidelines104. Incident diabetes was defined as having newly diagnosed diabetes at the 5-, 10-, or 
15-year follow-up examination among subjects free of diabetes at baseline. 
 
2.2.4 Statistical methods 
 We were interested in the association between serum levels of sVCAM-1 and sICAM-1 
and 15-year incident diabetes. We categorized VCAM and ICAM into tertiles for the main 
analysis.  
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We used chi-square test and analysis of variance to compare the relationship of selected baseline 
characteristics to increasing categories of VCAM. We used multivariable Cox proportional 
hazard regression models to determine the hazard ratio (HR) and 95 percent confidence interval 
(CI) of 15-year incident diabetes, controlling simultaneously for potential confounders. We used 
a multivariable-adjusted Cox proportional hazard regression model, adjusted for age, gender 
(female, male), education (<high school, high school, >high school), smoking (never, former, 
current), alcohol intake (never, former, current), BMI (kg/m2), hypertension (absent, present), 
mean arterial blood pressure (mm Hg), serum total cholesterol (mg/dL) and high sensitivity C-
reactive protein (mg/dL). To examine the consistency of the association between sVCAM-1 and 
sICAM-1 levels and incident diabetes, we performed subgroup analyses by gender (men, 
women) and hypertensive status (yes, no). 
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2.3 RESULTS 
Among 1119 study participants included in the current analysis, there were 472 men and 
647 women. Overall, 156 subjects (13.9%) developed diabetes over an average 15-year follow-
up period, including 83 men and 73 women.  
Table 2.1 presents the characteristics of the study population by increasing serum 
sVCAM-1 levels at baseline. Those who had higher serum sVCAM-1 levels were more likely to 
be older, educated below high school, never smokers and never or former drinkers. They were 
also likely to have hypertension, lower total serum cholesterol levels and higher systolic blood 
pressure. 
Table 2.2 presents the association between increasing categories of serum sVCAM-1, 
sICAM-1 and 15-year incident diabetes. The multivariable model for sVCAM-1 showed a 
positive association between increasing serum sVCAM-1 levels and incident diabetesSimilarly, 
the multivariable model for sICAM-1 showed a positive association between increasing serum 
sICAM-1 levels and incident diabetes and the model evaluating linear trend in this association 
was similarly just shy of statistical significance (p-trend=0.0623).  
Table 2.3 presents the associations between increasing categories of serum sVCAM-1, 
sICAM-1 and 15-year incident diabetes, stratified by gender. The multivariable model for 
sVCAM-1 in women showed no association between increasing serum sVCAM-1 levels and 
incident diabetes. In contrast, the multivariable model for sVCAM-1 in men showed a positive 
association between increasing serum sVCAM-1 levels and incident diabetes. The model 
evaluating the trend was statistically significant. Similarly, the multivariable model for sICAM-1 
in women showed no association between increasing serum sICAM-1 levels and incident 
diabetes. In contrast, the multivariable model for sICAM-1 in men showed a positive association 
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between increasing sICAM-1 levels and incident diabetes. The model evaluating the trend was 
statistically significant. 
Table 2.4 presents the associations between increasing categories of serum sVCAM-1, 
sICAM-1 and 15-year incident diabetes, stratified by hypertension status. The multivariable 
model for sVCAM-1 in those without hypertension showed no association between increasing 
serum sVCAM-1 levels and incident diabetes. In contrast, the multivariable model for sVCAM-
1in those with hypertension showed a positive association between increasing serum sVCAM-1 
levels and incident diabetes.  The model evaluating the trend was just shy of statistical 
significance.  For sICAM-1, a similar pattern of association with incident diabetes was observed, 
with no association among those without hypertension and a positive association among those 
with hypertension. The model evaluating the trend was statistically significant. 
Supplementary analyses were conducted to examine the association between serum 
sVCAM-1 and sICAM-1 and incident diabetes, stratified by obesity status. We found that serum 
sVCAM-1 and sICAM-1 were related to incident diabetes both among non-obese and obese 
subjects. Compared to the lowest tertile of sVCAM-1 (referent), the multivariable odds ratio 
(95% confidence interval) of incident diabetes was 1.45 (0.79, 2.66) in tertile 2 and 1.97 (1.06-
3.67) in tertile 3 in obese subjects, and 1.01 (0.50, 2.01) in tertile 2 and 1.60 (0.88-2.90) in tertile 
3 in non-obese subjects; p-interaction=0.1452. Results were similar for sICAM-1. 
A second set of supplementary analyses were conducted to examine the association 
between serum sVCAM-1 and sICAM-1 and incident diabetes, additionally adjusted for baseline 
glycosolated hemoglobin in the multivariable model.  Compared to the lowest tertile of sVCAM-
1 (referent), the multivariable odds ratio (95% confidence interval) of incident diabetes was 1.59 
(1.03, 2.46) in tertile 2 and 1.67 (1.04-2.68) in tertile 3.  Compared to the lowest tertile of 
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sICAM-1 (referent), the multivariable odds ratio (95% confidence interval) of incident diabetes 
was 1.29 (0.62, 2.68) in tertile 2 and 1.67 (1.00-2.79) in tertile 3.  
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2.4 DISCUSSION 
In a population-based sample of adults from Wisconsin, increasing serum levels of 
sVCAM-1 and sICAM-1 were found to be positively associated with incident diabetes mellitus 
in men, and in subjects with hypertension. In contrast, serum levels of sICAM-1 and sVCAM-1 
were not found to be associated with diabetes mellitus in women, or in subjects without 
hypertension. These contrasting associations were independent of smoking, alcohol intake, 
education, hypertension, body mass index, total cholesterol and high sensitivity C - reactive 
protein levels. 
Serum levels of sICAM-1 and sVCAM-1 have been used in epidemiological research 
before as reliable markers of endothelial dysfunction.97 Previous studies have reported that 
markers of endothelial dysfunction are associated with increased risk of developing 
cardiovascular disease.94 As diabetes is one of the strong risk factors for cardiovascular disease, 
we examined if endothelial dysfunction markers are also related to diabetes mellitus. 
Subsequently we found that markers of endothelial dysfunction are related to diabetes in men 
and subjects with hypertension.  
Our study results of an association between markers of endothelial dysfunction and 
diabetes in men are consistent with a previous study by Thorand et al. showing serum  sICAM-1 
levels to be associated with increased risk of type 2 diabetes in men and not in women, with 
hazard ratios of 1.32 and 1.03, respectively.84  Also, another study showed that when measuring 
endothelial function as reactive hyperemia by peripheral arterial tonometry, endothelial 
dysfunction was associated in adolescent males but not adolescent females.83  However, our 
findings are inconsistent with previous research reporting sVCAM-1 and sICAM-1 to be 
associated with diabetes in elderly women.98-100   
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Several metabolic abnormalities associated with diabetes mellitus are thought to 
contribute to endothelial dysfunction by disrupting mechanisms that regulate nitric oxide 
synthesis, including conditions such as hyperglycemia, insulin resistance, excess free fatty acids 
release and compensatory hyperinsulinemia.105  Therefore, it would be plausible for diabetes 
mellitus to be associated with endothelial dysfunction. 
The correct explanation for the lack of association between markers of endothelial 
dysfunction and diabetes in women in the current study is not clear. One explanation may be that 
female hormones are cardioprotective and therefore to some extent may mitigate any adverse 
effect of endothelial dysfunction.106 There is a need for more studies in this topic to clarify the 
modifying effect of female gender in the association between endothelial dysfunction and 
diabetes. 
In the current study we found that markers of endothelial dysfunction are associated with 
diabetes among subjects with hypertension. It has been shown that endothelial dysfunction is one 
of the hallmarks of hypertension107-109.  Diabetes and hypertension are known to occur together 
as part of the insulin resistance syndrome110 and as per the "common soil" hypothesis,111as they 
may share common antecedents, such as adverse environmental conditions and less than optimal 
nutrition. A corollary observation to our findings is that along with insulin resistance, endothelial 
dysfunction may be one of the antecedent factors shared by hypertension and diabetes mellitus. 
Strengths of this study include its population-based sample, high participation rate, use of 
standardized protocols for exposure and outcome measurement and the availability of specific 
markers of endothelial dysfunction, including sVCAM-1 and sICAM-1 levels. Also, 
misclassification of diabetes status may have biased our results. A main study limitation is the 
generalizability of our study to other populations.  
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In conclusion, in a population-based sample of Wisconsin adults, we found that 
increasing serum levels of sVCAM-1 and sICAM-1 levels were positively associated with 15-
year incident diabetes mellitus in men and in subjects with hypertension, independent of age 
smoking status, alcohol intake, education, hypertension, BMI,  total cholesterol levels and high 
sensitivity c-reactive protein levels. In contrast, serum levels of sICAM-1 and sVCAM-1 were 
not found to be associated with diabetes mellitus in women, or in subjects without hypertension.  
This finding may suggest sVCAM-1 and sICAM-1 to be a novel risk factor risk factor in the 
development of diabetes mellitus in men and in those with hypertension. 
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2.5 TABLES  
Table 2.1. Baseline characteristics by vascular cell adhesion molecule 1 (sVCAM -1) tertiles 
 Serum SVCAM-1 tertiles*  
Characteristics Tertile 1 Tertile 2 Tertile 3 p-value† 
Age, years 55.6 ± 0.51 58.40 ± 0.51 63.49 ± 0.51 < 0.0001 
Females, % 56.2% 58.2% 59.1% 0.7243 
Education, %    < 0.0001 
     Below high school 14.6% 18.2% 27.8%  
     High school 47.3% 48.6% 43.6%  
     Above high school 38.1% 33.2% 28.6%  
Smoking, %    0.1765 
     Never 43.5% 44.8% 49.6%  
     Former 32.4% 33.4% 33.3%  
     Current 24.1% 21.7% 17.1%  
Alcohol intake categories, %    0.0062 
     Never 1.1% 3.0% 4.7%  
     Former 5.7% 7.3% 7.9%  
     Current drinker, <2 drinks/day 81.4% 81.3% 81.6%  
     Current drinker, ≥3 drinks/day 11.9% 8.4% 5.8%  
Body mass index (BMI), kg/m2 28.4 ± 0.28 28.2 ± 0.28 28.9 ± 0.28 < 0.0001 
Serum total cholesterol mg/dL 241.5 ± 2.25 232.5 ± 2.26 226.1 ± 2.22 < 0.0001 
Hypertension, % 39.2% 38.6% 52.0% 0.0002 
Systolic blood pressure, mm Hg 127.5 ± 0.98 127.7 ± 0.98 133.1 ± 0.97 < 0.0001 
Diastolic blood pressure, mm Hg 79.1 ± 0.54 77.3 ± 0.54 77.9 ± 0.53 < 0.0001 
*sVCAM-1 Tertiles : Tertile 1( ≤ 682.2 ng/ml) Tertile 2 (682.3-826.2 ng/ml) Tertile 3 (≥ 826.2 ng/ml) 
†p-value estimated by analysis of variance or chi-square test as appropriate 
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Table 2.2. Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident diabetes 
 
Serum sVCAM-1 tertiles* 
(n=1119) 
No. at 
risk Cases 
Multivariable-adjusted 
hazards ratio (95% confidence interval) ‡ 
Tertile 1  370 42 1 (referent) 
Tertile 2  368 60 1.63 (1.07, 2.49) 
Tertile 3  381 54 1.46 (0.93, 2.31) 
p-trend   0.1187 
    
Serum sICAM-1 tertiles † 
(n=1119)    
Tertile 1  370 43 1 (referent) 
Tertile 2  368 48 1.09 (0.71, 1.69) 
Tertile 3  381 65 1.52 (0.99, 2.33) 
p-trend   0.0528 
*sVCAM-1 Tertiles :Tertile 1( ≤ 682.2 ng/ml) Tertile 2 (682.3-826.2 ng/ml) Tertile 3 (≥ 826.2 ng/ml)  
†sICAM-1 Tertiles : Tertile 1( ≤ 247.5 ng/ml) Tertile 2 (247.6-302.2 ng/ml) Tertile 3 (≥ 302.2 ng/ml)  
‡Adjusted for age (years), sex (male, female), education categories (<high school, high school, >high school), 
smoking (never, former, current), alcohol intake (never, former, current), body mass index (kg/m2), hypertension 
(absent, present) and serum cholesterol (%), high sensitivity C reactive protein (mg/dl) 
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Table 2.3.  Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident diabetes, by gender§ 
 Women  Men 
 
No. at risk 
(diabetes cases) 
Multivariable-adjusted hazards 
ratio (95% confidence interval) ‡  
No. at risk 
(diabetes 
cases) 
Multivariable-adjusted hazards ratio 
(95% confidence interval) ‡ 
Serum sVCAM-1 tertiles* 
(n=1119)    
 
 
Tertile 1  208 (23) 1 (referent)  162 (19) 1 (referent) 
Tertile 2  214 (26) 1.06 (0.58, 1.93)  154 (34) 2.17, (1.16, 4.05) 
Tertile 3  225 (24) 0.90 (0.46, 1.77)  156 (30) 2.29 (1.18, 4.44) 
p-trend  0.7413   0.0157 
      
Serum sICAM-1 tertiles † 
(n=1119)    
 
 
Tertile 1  203 (22) 1 (referent)  167 (21) 1 (referent) 
Tertile 2  219 (21) 0.80 (0.43, 1.52)  149 (27) 1.51 (0.82, 2.77) 
Tertile 3  225 (30) 1.26 (0.69, 2.31)  156 (35) 1.88 (1.01, 3.48) 
p-trend  0.4086   0.0451 
*sVCAM-1 Tertiles :Tertile 1( ≤ 682.2 ng/ml) Tertile 2 (682.3-826.2 ng/ml) Tertile 3 (≥ 826.2 ng/ml)  
†sICAM-1 Tertiles : Tertile 1( ≤ 247.5 ng/ml) Tertile 2 (247.6-302.2 ng/ml) Tertile 3 (≥ 302.2 ng/ml)  
‡Adjusted for age (years), education categories (<high school, high school, >high school), smoking (never, former, current), alcohol intake (never, 
former, current), body mass index (kg/m2), hypertension (absent, present) and serum cholesterol (%), high sensitivity C reactive protein (mg/dl) 
§P-interaction for gender and sVCAM-1 = 0.1168 
§P-interaction for gender and sICAM-1 = 0.2164 
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Table 2.4.  Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident diabetes by hypertension status§ 
 No Hypertension  Hypertension 
 
No. at risk 
(diabetes cases) 
Multivariable-adjusted hazards 
ratio (95% confidence interval) ‡  
No. at risk 
(diabetes cases) 
Multivariable-adjusted hazards 
ratio (95% confidence interval) ‡ 
Serum sVCAM-1 tertiles* 
(n=1119)    
 
 
Tertile 1  225 (25) 1 (referent)  145 (17) 1 (referent) 
Tertile 2  226 (27) 1.08 (0.61, 1.93)  142 (33) 2.51 (1.32, 4.76) 
Tertile 3  183 (21) 1.07 (0.56, 2.05)  198 (33) 2.03 (1.03, 3.99) 
p-trend  0.8262   0.0556 
      
Serum sICAM-1 tertiles † 
(n=1119)    
 
 
Tertile 1  225 (24) 1 (referent)  145 (19) 1 (referent) 
Tertile 2  192 (21) 1.12 (0.60, 2.09)  176 (27) 1.17 (0.63, 2.18) 
Tertile 3  217 (28) 1.08 (0.58, 2.01)  164 (37) 2.04 (1.11, 3.76) 
p-trend  0.8022   0.0186 
*sVCAM-1 Tertiles :Tertile 1( ≤ 682.2 ng/ml) Tertile 2 (682.3-826.2 ng/ml) Tertile 3 (≥ 826.2 ng/ml)  
†sICAM-1 Tertiles : Tertile 1( ≤ 247.5 ng/ml) Tertile 2 (247.6-302.2 ng/ml) Tertile 3 (≥ 302.2 ng/ml)  
‡Adjusted for age (years), sex (male, female), education categories (<high school, high school, >high school), smoking (never, former, 
current), alcohol intake (never, former, current), body mass index (kg/m2),and serum cholesterol (%), high sensitivity C reactive protein (mg/dl) 
§P-interaction for hypertension and sVCAM-1 = 0.3674 
§P-interaction for hypertension and sICAM-1 = 0.1975 
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Manuscript 2: The Association of Markers of Endothelial 
Dysfunction and Incident Hypertension 
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3.1 INTRODUCTION 
Endothelial dysfunction is a key pathophysiological process involved in the development of 
cardiovascular disease.76  Endothelial dysfunction has also been shown to precede the 
development of hypertension in animal models112,113. However the relationship between markers 
of endothelial dysfunction and hypertension development in humans is not clear. Soluble 
adhesion molecules, including serum levels of vascular cell adhesion molecule-1 (sVCAM-1) 
and intercellular adhesion molecule -1 (sICAM-1) have been used as reliable markers of 
endothelial dysfunction in epidemiological studies.114   In humans, markers of endothelial 
dysfunction have been associated with hypertension in pregnant women,85 subjects with type 1 
diabetes86 and those with obstructive sleep apnea-hypopnea syndrome.87  Also, in the general 
population, Zhang et al88 showed that there was a positive association between sICAM-1 and E-
selectin levels and hypertension in a cross-sectional survey from China. However, to our 
knowledge, no epidemiological study has examined the relationship between soluble adhesion 
molecules and the longitudinal risk of developing hypertension in the general population. In this 
context, we examined the relation between serum levels of sVCAM-1 and sICAM-1 and the 
cumulative incidence of hypertension over a period of 10 years in a population-based sample of 
adults from Wisconsin. 
 27 
 
3.2 METHODS 
3.2.1 Population  
 
The current study is based on data from the Beaver Dam Eye study, a population-based 
cohort study in Wisconsin. The methods used to identify and describe the Beaver Dam 
population have appeared in previous reports.115,116 In brief, a private census of the population of 
Beaver Dam, Wisconsin, was performed from September 1987 to May 1988 to identify all 
residents in the city or township of Beaver Dam who were 43-84 years of age. Of the 5,924 
eligible individuals (98% Caucasians), 4,926 (83.1%) participated in the baseline examination 
between March 1, 1988 and September 14, 1990. Comparisons between participants and 
nonparticipants at the time of the baseline examination have appeared elsewhere.116  
The baseline examination was followed by a four follow-up examinations 5 year apart.  
We limit our analyses to the first 10-years of follow-up. Written informed consent was obtained 
from each subject at each examination. The study was approved by the Human Subjects 
Committee of the University of Wisconsin School of Medicine and Public Health, Madison, WI. 
Levels of sVCAM-1 and sICAM-1 were measured in stored frozen serum on a random sample of 
the baseline cohort (n=1793) as part of an ancillary study examining risk factors for kidney 
disease.  
For the longitudinal analyses with sVCAM-1 and sICAM-1 as the main exposure, out of 
1793 individuals with available sVCAM-1 and sICAM-1 measurements who participated in the 
baseline and at least the 5- or 10-year follow-up examination, we excluded subjects with 
prevalent hypertension at baseline (n=884) and missing information on covariates included in the 
multivariable model (n=28) . This resulted in 881 participants without hypertension with 
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complete biomarker and covariate information at baseline who were to form the at-risk 
population. 
 
3.2.2 Exposure ascertainment 
The baseline and follow-up examinations included measurement of weight, height, 
systolic and diastolic blood pressure by trained observers and administering a standardized 
questionnaire that collected information regarding participants’ demographic characteristics, 
details regarding cigarette smoking, alcohol intake, medical histories and medications taken, 
including physician-diagnosed diabetes, hypertension or cardiovascular disease (CVD). Non-
fasting blood specimens were obtained for measurement of plasma glucose, glycosylated 
hemoglobin, serum total cholesterol and high density lipoprotein (HDL) cholesterol.  
Age was defined as the participants’ age at the time of the baseline examination. 
Education was categorized as less than high school, high school, or beyond high school. Body 
mass index (BMI) was defined as participants’ weight in kilograms divided by their height in 
meters squared.  Diabetes mellitus was defined by use of using insulin, oral hypoglycemic 
agents, or were newly classified as having diabetes based on the glycosylated hemoglobin value 
that was ≥ 6.5%, consistent with recent American Diabetes Association guidelines.104 Chronic 
kidney disease was defined as having chronic kidney disease were defined as having an 
estimated glomerular filtration rate (GFR) of <60 ml/min per m2, estimated from serum 
creatinine employing the re-expressed Modification of Diet in Renal Diseases (MDRD) study 
equation.117 
At cohort examinations, blood samples were collected in three 10-mL liquid EDTA blood 
tubes, placed on ice packs, stored in Styrofoam containers until they were centrifuged and 
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aliquoted for storage in freezers at –800C until the time of laboratory analysis. Quality control 
samples were routinely frozen with study participant samples. Baseline frozen plasma samples 
were randomly ordered (to further reduce systematic bias and inter assay variation) and thawed 
and batch-analyzed for markers of endothelial function (sVCAM-1, sICAM-1). 
sVCAM-1 (soluble vascular cell adhesion molecule-1) was measured in plasma or serum 
using the quantitative sandwich enzyme technique of the enzyme-linked immunosorbent assay 
(ELISA) Parameter kit from R & D Systems (Minneapolis, MN).  The intensity of the color was 
measured on a SpectraMax spectrophotometer (Molecular Devices, Sunnyvale, California).  The 
inter-assay CV range was 8.9-10.2% for the plasma assay. 
sICAM-1 (soluble intercellular adhesion molecule-1) was measured in plasma using the 
quantitative sandwich enzyme technique of the enzyme-linked immunosorbent assay (ELISA) 
Parameter kit from R & D Systems (Minneapolis, MN).  The intensity of the color was measured 
on a SpectraMax spectrophotometer (Molecular Devices, Sunnyvale, California).  The inter-
assay CV range was 6.0-10.1% for the plasma assay.  
 
3.2.3 Outcome of interest: Hypertension 
 Hypertension was defined as having a systolic blood pressure of 140 mmHg or higher, 
and/or a diastolic blood pressure 90 mmHg or higher, and/or the combination of self-reported 
hypertension diagnosis by a physician and use of antihypertensive medications.  Incident 
hypertension was defined as having newly diagnosed hypertension at the 5-, or 10 year follow-up 
examination among subjects free of hypertension at baseline. 
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3.2.4 Statistical methods 
 We examined the association between serum levels of sVCAM-1 and sICAM-1 and 10-
year incident hypertension. We categorized sVCAM-1and sICAM-1 into quartiles for the main 
analysis.  We also analyzed these markers as continuous variables, as per standard deviation 
increase. We used chi-square test and analysis of variance to compare the relationship of selected 
baseline characteristics by increasing categories of sVCAM-1 and sICAM-1. We used 
multivariable Cox proportional hazard regression models to determine the hazard ratio (HR) and 
95 percent confidence interval (CI) of 10-year incident hypertension, controlling simultaneously 
for potential confounders, including age, gender (female, male), education (<high school, high 
school, >high school), smoking (never, former, current), alcohol intake (never, former, current), 
BMI (kg/m2), diabetes (absent, present), serum total cholesterol (mg/dL), chronic kidney disease 
(absent, present) and self-reported history of cardiovascular disease (absent, present).   To further 
validate the associations between categories of sVCAM-1 and sICAM-1, we stratified by gender 
(men, women), current smoking status (yes, no), obesity status (absent, present), diabetes status 
(absent, present), glycosylated hemoglobin levels (%), and chronic kidney disease status (absent, 
present). All analyses were performed in SAS version 9.2 (SAS Institute, Cary, NC).
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3.3 RESULTS 
Among 881 study participants included in the current analysis, there were 390 men and 
491 women. Overall, 257 subjects (29%) developed hypertension over an average 10-year 
follow-up period, including 106 men and 151 women.  
Table 3.1 presents the characteristics of the study population by increasing serum 
sVCAM-1 levels at baseline. Those who had higher serum sVCAM-1 levels were more likely to 
be older, never or former smokers. They were also likely to have higher systolic blood pressure 
but lower diastolic blood. 
Table 3.2 presents the association between increasing categories of serum sVCAM-1, 
sICAM-1 and 10-year incident hypertension. The multivariable model for sVCAM-1 showed a 
positive association between increasing serum sVCAM-1 levels and incident hypertension. The 
model evaluating the trend was statistically significant (p-trend=0.0005). However, the 
multivariable model for sICAM-1 showed no positive association between increasing serum 
sICAM-1 levels and incident hypertension (p-trend=0.3203).  
Table 3.3 presents the association between increasing categories of serum sVCAM-1 and 
sICAM-1 and 10-year incident hypertension by gender.  For sVCAM-1, the multivariable model 
showed a positive association with incident hypertension in women as well as men. However, for 
sVCAM-1 there was no association with incident hypertension in either sex.  
Table 3.4 presents the associations between increasing categories of serum sVCAM-1, 
sICAM-1 and incident hypertension, stratified by smoking, obesity, diabetes, and chronic kidney 
disease status. Here also, generally in agreement with Table 2, the multivariable model for 
sVCAM-1 showed a positive association with incident hypertension, but not for sICAM-1. 
Formal statistical tests for interaction were not significant (all p-interactions>0.10). 
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In a supplementary analysis when we adjusted for additional factors that may serve as 
confounders, including the use of medications that may affect endothelial function such as statins 
(current user, nonuser) and aspirin (current user, nonuser), and novel biomarkers such as high 
sensitivity C-reactive protein level (mg/dL) and serum uric acid (mg/dL), the association 
between increasing sVCAM-1 and sICAM-1 and hypertension remained materially the same. For 
sVCAM1, compared to quartile 1 (referent), the multivariable HR (95% CI) of incident 
hypertension was 1.39 (0.92, 2.10) in quartile 2, 1.75 (1.16, 2.64) in quartile 3, and 1.98 (1.39, 
2.82); p-trend=0.0004. Also, for sICAM-1, compared to quartile 1 (referent), the multivariable 
HR (95% CI) of incident hypertension was 1.29 (0.81, 2.05) in quartile 2, 1.09 (0.74, 1.61) in 
quartile 3, and 1.18 (0.80, 1.74); p-trend=0.432. 
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3.4 DISCUSSION 
In a population-based sample of adults from Wisconsin, increasing serum levels of 
sVCAM-1 were found to be positively associated with incident hypertension, independent of 
smoking, alcohol intake, education, hypertension, body mass index, serum total cholesterol, and 
chronic kidney disease. Serum sICAM-1, in contrast, was not found to be associated with 
hypertension. 
Serum levels of sVCAM-1 and sICAM-1 have been used previously in epidemiological 
research as reliable markers of endothelial dysfunction.114  Previous studies have reported that 
markers of endothelial dysfunction are associated with increased risk of developing 
cardiovascular disease.76 As hypertension is a strong risk factor for cardiovascular disease, we 
examined if endothelial dysfunction markers are also related to hypertension. Subsequently we 
found that serum sVCAM-1 was positively related to incident hypertension in both men and 
women. 
The observed association between endothelial dysfunction and hypertension may be due 
to endothelial damage and dysfunction impairing the vasodilator mechanism of endothelium-
derived relaxing factor (nitric oxide), subsequently causing elevated blood pressure.63 
Endothelial dysfunction may also be related to other mechanisms involved in the development of 
hypertension, including insulin resistance64, systemic inflammation65 and hyperuricemia.66 
However, in the current study, in a supplementary analysis, the association between sVCAM-1 
and hypertension was found to be attenuated, but still present, after adjustment for markers of 
inflammation and uric acid, suggesting that these mechanisms may only partially explain the 
observed association. 
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Our findings are consistent with one previous prospective epidemiological study 
examining the relationship between biomarkers of endothelial dysfunction and hypertension in 
those with type 1 diabetes86 and another cross-sectional study conducted in China.88  However, 
another epidemiological study, the Multiethnic Study of Atherosclerosis (MESA), found no 
association of endothelial dysfunction measured by brachial artery flow mediated-dilation with 
incident hypertension.118 The reason for this discrepancy in findings with our study is not clear. 
It is possible that serum levels of cellular adhesion molecules and brachial artery flow-mediated 
dilatation may be measuring different aspects of endothelial function. For example, physiological 
monitoring of flow-mediated dilatation is considered to be more dynamic and probably acutely 
influenced by a subject's recent dietary119 or recent exposure to environmental pollution.120  Also, 
studies in animals121 and humans122 have suggested that under different conditions (e.g. 
prolonged hyperemic stimulus vs. transient increases in blood flow), flow mediated dilatation 
may occur by mechanisms that are independent of endothelial nitric oxide production.123 Another 
possibility is that there are potential racial/ethnic differences in the endothelial dysfunction-
hypertension association as our study consisted of 99% whites whereas the MESA was a 
multiethnic sample.  
The reasons for the differing results that we observed for sVCAM-1 and sICAM-1 with 
incident hypertension are not clear. It is possible that even though these adhesion molecules are 
similar in structure and are members of the cytokine-inducible immunoglobulin gene 
superfamily124. they have different functions. This notion is also supported by recent animal 
studies that have shown that VCAM-1, and not ICAM-1, plays a major role in the initiation of 
atherosclerosis125, and others that have reported differential expression patterns for these 
adhesion molecules with VCAM-1 being expressed more in atherosclerotic lesions whereas 
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ICAM-1 expression extending into uninvolved aorta and lesion protected regions126. However, 
there is a need for more human studies to validate or refute our findings. 
Strengths of this study include it being a large population-based cohort, high participation 
rate, use of standardized protocols for exposure and outcome measurement and the availability of 
specific markers of endothelial dysfunction, including sVCAM-1 and sICAM-1 levels. Our 
results possess strong internal validity as we adjusted for known confounders and also the results 
remained relatively consistent when we performed stratified analysis by confounders. Study 
limitations include selective survival, the potential variability of endothelial dysfunction tests and 
the limited generalizability of our study to other populations as this sample is a 99% white. 
In conclusion, in a population-based sample of Wisconsin adults, we found that 
increasing serum levels of sVCAM-1 were positively associated with 10-year incident 
hypertension, independent of age smoking status, alcohol intake, education, hypertension, BMI,  
total cholesterol levels, chronic kidney disease and history of cardiovascular disease. In contrast, 
serum sICAM-1 was not found to be associated with hypertension. 
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3.5 TABLES  
Table 3.1. Baseline characteristics by soluble vascular cell adhesion molecule 1 (sVCAM -1) Quartile
 
 Serum sVCAM-1 Quartile*  
Characteristics Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value†
Age, years 54.4 ± 0.68 56.5 ± 0.68 59.5 ± 0.68 64.6 ± 0.68 < 0.0001
Females, % 58.4% 55.3% 55.7% 53.6% 0.7924
Education, %     < 0.0001
     Below high school 17.6% 12.3% 24.0% 31.8  
     High school 44.8% 54.8% 43.0% 43.6  
     Above high school 37.6% 32.9% 33.0% 24.6  
Smoking, %     0.0040
     Never 38.5% 41.6% 42.5% 43.6  
     Former 30.8% 33.3% 34.8% 42.3  
     Current 30.8% 25.1% 22.6% 14.1  
Alcohol intake categories, %     0.0583
     Never 0.9% 1.8% 1.8% 3.6%  
     Former 10.0% 8.2% 9.5% 11.8%  
     Current drinker, <2 drinks/day 79.2% 81.3% 84.6% 80.9%  
     Current drinker, ≥3 drinks/day 10.0% 8.7% 4.1% 3.6%  
Body mass index (BMI), kg/m2 27.6 ± 0.35 27.8 ± 0.35 27.8 ± 0.35 27.8 ± 0.35 < 0.0001
Serum total cholesterol, mg/dL 236.2 ± 2.86 233.3 ± 2.87 227.1 ± 2.86 218.6 ±2.86 < 0.0001
Diabetes mellitus, % 3.2% 1.8% 6.8% 6.8% 0.0219
Systolic blood pressure, mm Hg 117.5 ± 0.76 118.6 ± 0.76 118.9 ± 0.76 120.7 ± 0.76 < 0.0001
Diastolic blood pressure, mm Hg 74.1 ± 0.58 73.7 ± 0.58 73.7 ± 0.58 71.5 ± 0.58 < 0.0001
*sVCAM-1 Quartile : Quartile 1( ≤ 641.0 ng/ml) Quartile 2 (641.2-759.1 ng/ml) Quartile 3 (759.2-887.6) Quartile 4 (≥887.6 ng/ml)
†p-value estimated by analysis of variance or chi-square test as appropriate
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Table 3.2. Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident hypertension
Serum sVCAM-1 quartiles* 
No. at risk 
(n=881)
Incident 
Hypertension 
(n=257)
Unadjusted hazards ratio (95% 
confidence interval) 
Multivariable-adjusted 
hazards ratio (95% confidence interval) ‡
Quartile 1  221 46 1 (referent category) 1 (referent category)
Quartile 2  219 65 1.44 (0.95, 2.18) 1.47 (0.96, 2.26)
Quartile 3  221 72 1.81 (1.20, 2.74) 1.78 (1.17, 2.73)
Quartile 4  220 74 2.48 (1.63, 3.76) 2.14 (1.42, 3.23)
     p-trend    < 0.0001 0.0003
     
Serum sICAM-1 quartiles†     
Quartile 1  221 56 1 (referent category) 1 (referent category)
Quartile 2  219 66 1.33 (0.89, 1.98) 1.33 (0.88,  2.00)
Quartile 3  221 69 1.36 (0.91, 2.01) 1.15 (0.76, 1.74)
Quartile 4  220 66 1.58 (1.05, 2.36) 1.26 (0.85, 2.09)
     p-trend   0.0322 0.3603
     
*sVCAM-1 Quartiles: Quartile 1 (0-641.0 (ng/ml)), Quartile 2 (641.1-759.1 ng/ml), Quartile 3 (759.2-887.6), Quartile 4 ( > 887.6 ng/ml)
†sICAM-1 Quartiles: Quartile 1 (0-233.9 (ng/ml)), Quartile 2 (234.0-277.8 ng/ml), Quartile 3 (277.9-334.2), Quartile 4 ( > 334.2 ng/ml) 
‡Adjusted for age (years), gender (male, female) ,education categories (<high school, high school, >high school), smoking (never, former, 
current), alcohol intake (never, former, current), body mass index (kg/m2), diabetes (absent, present), glycosylated hemoglobin (%), 
chronic kidney disease (absent, present),  history of cardiovascular disease (absent, present) and serum cholesterol (mg/dL)
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Table 3.3. Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident hypertension stratified by gender.
 Men (n=390) Women (n=491)
Serum sVCAM-1 quartiles*  
Multivariable-adjusted
hazards ratio (95% confidence interval) ‡ 
Multivariable-adjusted
hazards ratio (95% confidence interval) ‡
Quartile 1  1 (referent category) 1 (referent category)
Quartile 2  0.97 (0.48, 1.94) 1.95 (1.11, 3.40)
Quartile 3  1.69 (0.89, 3.21) 1.88 (1.05, 3.36)
Quartile 4  1.81 (1.01, 3.24) 2.86 (1.57, 5.22)
     p-trend 0.0440 0.0013
   
Serum sICAM-1 quartiles†    
Quartile 1  1 (referent category) 1 (referent category)
Quartile 2  1.04 (0.55, 1.97) 1.59 (0.92, 2.77)
Quartile 3  0.84 (0.43, 1.65) 1.39 (0.83, 2.33)
Quartile 4  1.35 (0.71, 2.57) 1.28 (0.71, 2.31)
     p-trend 0.5100 0.4798
   
* sVCAM-1: soluable vascular cell adhesion molecule-1; sVCAM Quartiles Quartile 1 (0-641.0 (ng/ml)), Quartile 2 (641.1-759.1 ng/ml), 
Quartile 3 (759.2-887.6), Quartile 4 ( > 887.6 ng/ml) 
†sICAM-1: soluable intercellular adhesión molecule-1; sICAM Quartiles: Quartile 1 (0-233.9 (ng/ml)), Quartile 2 (234.0-277.8 ng/ml), 
Quartile 3 (277.9-334.2), Quartile 4 ( > 334.2 ng/ml) 
‡Adjusted for age (years), education categories (<high school, high school, >high school), smoking (never, former, current), alcohol intake 
(never, former, current), body mass index (kg/m2), diabetes (absent, present), glycosylated hemoglobin (%), chronic kidney disease (absent, 
present),  history of cardiovascular disease (absent, present) and serum cholesterol (mg/dL) 
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 Table 3.4. The association by sVCAM-1 and sICAM-1 and incident hypertension in selected subgroups
Categories No. at risk 
sVCAM-1
The multivariable-adjusted hazards 
ratio† (95% confidence interval) for 
one standard deviation increase‡
sICAM-1
The multivariable-adjusted hazards 
ratio† (95% confidence interval) for 
one standard deviation increase‡
Current Smoker    
   No 677 1.16 (0.96, 1.40) 0.98 (0.80, 1.19)
   Yes 204 1.26 (0.78, 2.04) 1.21 (0.88, 1.66)
Obesity    
   Absent  627 1.17 (0.93, 1.48) 1.05 (0.88, 1.25)
   Present 254 1.23 (0.81, 1.87) 0.88 (0.63, 1.23)
Diabetes        
   Absent 840 1.27 (1.01, 1.57) 1.05 (0.90, 1.23)
   Present 41 1.16 (0.67, 2.01) 0.28 (0.03, 2.46)
Chronic kidney disease    
   Absent 783 1.16 (0.95, 1.41) 1.12 (0.93, 1.35)
   Present 98 1.26 (0.70, 2.27) 0.55 (0.27, 1.12)
*All p-interactions > 0.10 
†  Adjusted for age (years), gender (male, female) ,education categories (<high school, high school, >high school), 
smoking (never, former, current), alcohol intake (never, former, current), body mass index (kg/m2), diabetes (absent, 
present), glycosylated hemoglobin (%), chronic kidney disease (absent, present),  history of cardiovascular disease 
(absent, present) and serum cholesterol (mg/dL); not adjusted for stratifying variable. 
‡  one standard deviation sVCAM-1 = 323.0 units; one standard deviation of sICAM-1 = 99.2 units
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4.1 INTRODUCTION 
 
Chronic kidney disease (CKD) is recognized as a risk factor for cardiovascular disease35,  
and it also independently predicts cardiovascular mortality.36 Endothelial dysfunction is one of 
the key pathophysiologic processes involved in the development of atherosclerotic vascular 
disease.127  Binding and recruitment of circulating leukocytes to the vascular endothelium and 
further migration into the subendothelial spaces are mediated through a diverse family of cellular 
adhesion molecules that are expressed on the surface of vascular endothelial cells, including 
sVCAM-1 and sICAM-1.128  Circulating levels of these adhesion molecules have been used as 
markers of endothelial function in epidemiologic studies.129 Studies have shown that markers of 
endothelial dysfunction, including sVCAM-1 and sICAM-1 are related to risk of developing 
diabetes mellitus130 and hypertension,131 two of the well known risk factors of CKD.  
Previous cross-sectional studies have shown that markers of endothelial function are 
related to kidney disease132-134. However, since endothelial function markers are also elevated 
secondary to CKD and dialysis,89,90,135 studies with longitudinal follow-up are required to 
examine whether endothelial dysfunction precedes CKD onset. Therefore, we examined 
biomarkers of endothelial dysfunction, including sVCAM-1 and sICAM-1 in relationship to the 
15-year cumulative incidence of CKD in a population-based sample of adults from Wisconsin. 
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4.2 METHODS 
4.2.1 Population 
The current study is based on data from the Beaver Dam Eye study, a population-based 
cohort study in Wisconsin originally aimed at studying age-related eye diseases. The methods 
used to identify and describe the Beaver Dam population have appeared in previous reports. 
115,116In brief, a private census of the population of Beaver Dam, Wisconsin, was performed from 
September 1987 to May 1988 to identify all residents in the city or township of Beaver Dam who 
were 43-84 years of age. Of the 5,924 eligible individuals (98% Caucasians), 4,926 (83.1%) 
participated in the baseline examination between March 1, 1988 and September 14, 1990. 
Comparisons between participants and nonparticipants at the time of the baseline examination 
have appeared elsewhere116.  
The baseline examination was followed by a 5-year follow-up examination from 1993 to 
1995, a 10-year follow-up examination from 1998-2000, and a 15-year follow-up examination 
from 2003-2005. Written informed consent was obtained from each subject at each examination. 
The study was approved by the Human Subjects Committee of the University of Wisconsin 
School of Medicine and Public Health, Madison, WI. Serum levels of sVCAM-1 and sICAM-1 
were measured on a random sample of the baseline cohort (n=1793) as part of an ancillary study 
examining risk factors for kidney disease.  
For the longitudinal analyses with sVCAM-1 and sICAM-1 as the main exposure, out of 
1793 individuals with available sVCAM-1 and sICAM-1 measurements who participated in the 
baseline and at least one follow-up examination, we excluded subjects with CKD at baseline 
(n=141), missing information on covariates included in the multivariable model (n=343) and 
 43 
 
those who had a history of cardiovascular disease (n=264). This resulted in n=1045 CKD-free 
individuals with biomarker complete covariate information to form the at-risk study population. 
 
4.2.2 Exposure ascertainment 
The baseline and follow-up examinations included measurement of weight, height, 
systolic and diastolic blood pressure by trained observers and administering standardized 
questionnaire that collected information regarding participants’ demographic characteristics, 
details regarding cigarette smoking, alcohol intake, medical histories and medications taken, 
including physician-diagnosed diabetes, hypertension or cardiovascular disease (CVD). Non-
fasting blood specimens were obtained for measurement of plasma glucose, glycosylated 
hemoglobin, serum total cholesterol and high density lipoprotein (HDL) cholesterol.  
Age was defined as the participants’ age at the time of the baseline examination. 
Education was categorized as less than high school, high school, or beyond high school. Body 
mass index (BMI) was defined as participants’ weight in kilograms divided by their height in 
meters squared. Hypertension was defined as a systolic blood pressure of 140 mmHg or higher, 
and/or a diastolic blood pressure 90 mmHg or higher, and/or the combination of self-reported 
hypertension diagnosis by a physician and use of antihypertensive medications.  
At cohort examinations, blood samples were collected in three 10-mL liquid EDTA blood 
tubes, placed on ice packs, stored in Styrofoam containers until they were centrifuged and 
aliquoted for storage in freezers at –800C until the time of laboratory analysis. Quality control 
samples were routinely frozen with study participant samples. Baseline frozen plasma samples 
were randomly ordered (to further reduce systematic bias and inter assay variation) and thawed 
and batch-analyzed for markers of endothelial function (sVCAM-1, sICAM-1). 
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sVCAM-1 (soluble vascular cell adhesion molecule-1) was measured in serum using the 
quantitative sandwich enzyme technique of the enzyme-linked immunosorbent assay (ELISA) 
Parameter kit from R & D Systems (Minneapolis, MN).  The intensity of the color was measured 
on a SpectraMax spectrophotometer (Molecular Devices, Sunnyvale, California).  The inter-
assay coefficient of variability (CV) range was 8.9-10.2%. 
sICAM-1 (soluble intercellular adhesion molecule-1) was measured in serum using the 
quantitative sandwich enzyme technique of the enzyme-linked immunosorbent assay (ELISA) 
Parameter kit from R & D Systems (Minneapolis, MN).  The intensity of the color was measured 
on a SpectraMax spectrophotometer (Molecular Devices, Sunnyvale, California).  The inter-
assay CV range was 6.0-10.1%.  
 
4.2.3 Outcome of Interest: Chronic Kidney Disease 
Chronic kidney disease was defined as having an estimated glomerular filtration rate 
(eGFR) of <60 ml/min per m2, using the re-expressed Modification of Diet in Renal Diseases 
(MDRD) study equation 117 to estimate GFR for the main analysis and the CKD-EPI equation in 
a supplementary analysis to verify the results.136  Incident CKD was defined as having newly 
diagnosed CKD at the 5-, 10-, or 15-year follow-up examination among subjects free of CKD at 
baseline. 
 
4.2.4 Statistical methods 
 We were interested in the association between markers of endothelial dysfunction 
(sVCAM-1 and sICAM-1 levels) and incident CKD.  We categorized sVCAM-1 and sICAM-1 
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into quartiles for the main analysis. We also analyzed these markers as continuous variables after 
logarithmic transformation due to their skewed distribution.  
We used chi-square test and analysis of variance to compare the relationship of selected 
baseline characteristics to incident CKD status. We used multivariable Cox proportional hazard 
regression models to determine the hazard ratio (HR) and 95 percent confidence interval (CI) of 
15-year incident CKD, controlling simultaneously for potential confounders. We used two nested 
Cox proportional hazard regression models: an unadjusted model and a multivariable-adjusted 
model, additionally adjusted for age, gender (male, female), education (<high school, high 
school, >high school), smoking (never, former, current), alcohol intake (never, former, current), 
BMI (kg/m2), hypertension (absent, present), diabetes (absent, present)  mean arterial blood 
pressure (mm Hg), and serum total cholesterol (mg/dL).   To further validate the associations 
between increasing categories of sVCAM-1 and sICAM-1, we stratified by gender (men, 
women) and hypertension status (hypertension, no hypertension). 
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4.3 RESULTS 
Among 1045 Wisconsin adults ≥43 years of age included in the current analysis, there 
were 466 men and 579 women. Overall, 269 subjects developed CKD, including 107 men and 
162 women.  
Table 4.1 presents the characteristics of the study population by chronic disease status. 
Those who had CKD were more likely to be older, female, have less than a high school 
education, be never smokers, current or former drinkers, have hypertension and have higher 
BMI, serum total cholesterol, and systolic and diastolic blood pressures. 
Table 4.2 presents the associations between increasing categories of sVCAM-1, sICAM-1 
and the 15-year cumulative incidence of CKD. The unadjusted-model for sVCAM-1 showed a 
positive association between increasing levels of sVCAM-1 and incident CKD. However, the 
multivariable-model for sVCAM-1 showed no association between increasing levels of sVCAM-
1 and incident CKD.  Neither the unadjusted or multivariable models for sICAM-1 showed an 
association between increasing levels of sICAM-1 and incident CKD.  
Table 4.3 presents the associations between increasing categories of sVCAM-1 and 
sICAM-1 and 15-year incident CKD by gender. For both men and women, the multivariable 
model for sVCAM-1 as well as sICAM-1 showed no association between increasing levels of 
these markers and incident CKD. 
Table 4.4 presents the associations between increasing categories of sVCAM-1 and 
sICAM-1 and 15-year incident CKD by hypertension status. For both without and with 
hypertension, the multivariable model for sVCAM-1 as well as sICAM-1 showed no association 
between increasing levels of these markers and incident CKD. 
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In a supplementary analysis, to examine the robustness of our findings, we analyzed the 
associations between increasing categories of sVCAM-1, sICAM-1 and 15-year incident CKD, 
employing the CKD-EPI equation instead of the MDRD equation; the results were found to be 
essentially similar with no association between these markers and incident CKD. For sVCAM-1, 
compared to quartile 1 (referent), the multivariable hazards ratio (95% confidence interval) of 
incident CKD was 0.77 (0.46, 1.28) in quartile 2, 1.16 (0.73, 1.85) in quartile 3, and 0.90 (0.55, 
1.45) in quartile 4; p-trend=0.9471. For ICAM-1, compared to quartile 1 (referent), the 
multivariable hazards ratio (95% confidence interval) of incident CKD was 1.15 (0.71, 1.86) in 
quartile 2, 1.43 (0.91, 2.27) in quartile 3, and 1.20 (0.73, 1.99) in quartile 4; p-trend=0.3082. 
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4.4 DISCUSSION 
In a population-based sample, after adjusting for lifestyle and medical risk factors, 
including gender, smoking status, alcohol intake, education, hypertension, body mass index and 
total cholesterol increasing levels of sVCAM-1 and sICAM-1 were not associated with incident 
CKD.  
The vascular endothelium is involved in a variety of key processes important to human 
health and disease, including control of coagulation137, fibrinolysis137,138 vascular tone137,139  and 
growth139, immune response137,139, and oxidative stress138,140. Endothelial dysfunction has been 
found to be closely related to insulin resistance141,142, elevated levels of inflammatory 
markers141,143, impaired function of lipoprotein lipase (contributing to high triglycerides and low 
HDL cholesterol levels)141,143, impaired nitric oxide release143  and endothelium dependent 
vasodilation143.  Endothelial dysfunction is also present in end-stage renal disesease134,144. 
Biomarkers of endothelial dysfunction, including circulating adhesion molecules VCAM-1 and 
ICAM-1 have been shown to be elevated even in less advanced stages of kidney disease132-134.  
Several lines of recent evidence from animal studies support this hypothesis that 
biomarkers of endothelial dysfunction may predict CKD. Janssen et al.145reported that ICAM-1 
knockout mice developed significantly less severe experimentally induced nephrotoxic nephritis 
and glomerular crescents compared to control mice. Similarly, Kawasaki et al. showed that 
injection of antibodies against ICAM-1 prevented glomerular injury in experimental crescentic 
glomerular nephritis146. To our knowledge, this is the first prospective study in humans to 
examine the association between endothelial dysfunction and the development of renal disease 
using circulating levels of cellular adhesion molecules.  Circulating levels of cellular adhesion 
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molecules are specific and valid markers of endothelial dysfunction and have been used 
extensively in epidemiologic studies that utilized stored biospecimen130,131. 
 In the current study, we found that sVCAM-1 levels were initially moderately associated 
with CKD in the unadjusted model but after adjusting for lifestyle and medical risk factors, the 
association was no longer present.  In contrast, sICAM-1 levels were not associated with CKD in 
the unadjusted as well as the multivariable-adjusted model. The reasons for the observed 
differential associations in CKD in the unadjusted model for sVCAM-1 and sICAM-1 are not 
clear. Analogous to the recently reported differential associations of these adhesion molecules in 
the brain microvasculature,147 it is possible that VCAM-1 and ICAM-1  may have differential 
roles in leukocyte adhesion in renal microvessels also, with probably sVCAM-1 playing the 
major role of leukocyte recruitment in kidneys. 
 This study has high internal validity as we adjusted for the main confounders and 
performed stratified analyses by gender and hypertension status.  Also, in contrast to Perticone, 
et al148 who reported an association between endothelial dysfunction markers and CKD among 
those with hypertension, the null association that we observed between markers of endothelial 
dysfunction and CKD was consistently present in those with and without hypertension. 
Strengths of this study include its population-based sample, high participation rate, use of 
standardized protocols for exposure and outcome measurement and the availability of specific 
markers of endothelial dysfunction, including sVCAM-1 and sICAM-1 levels. Our results of no 
association between markers of endothelial dysfunction and incident CKD possess strong 
internal validity as we adjusted for known confounders and also the results remained relatively 
consistent when we performed stratified analysis by gender. A main study limitation is the 
 50 
 
generalizability of our study to other populations as this sample is a 99% white and is greater 
than or equal to 43 years of age. 
In conclusion, in a population-based sample of adults from Wisconsin, increasing levels 
of sVCAM-1 and of sICAM-1 were not associated with incident CKD.  Therefore, markers of 
endothelial dysfunction such as sVCAM-1 and sICAM-1 may not be independently associated 
with CKD. 
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4.5. TABLES  
Table 4.1. Baseline characteristics by chronic kidney disease (CKD) status
 CKD status  
Characteristics No CKD CKD p-value†
Age, years 57.3 ± 0.35 61.7 ± 0.59 <0.0001
Females, % 53.7% 60.2% 0.0652
Education, %   0.0005
     Below high school 16.8% 27.1%  
     High school 49.9% 40.2%  
     Above high school 33.4% 32.7%  
Smoking, %   0.0314
     Never 41.9% 50.2%  
     Former 36.7% 28.6%  
     Current 21.4% 21.2%  
Alcohol intake categories, %   0.4570
     Never 3.1% 2.6%  
     Former 7.0% 7.4%  
     Current drinker, <2 drinks/day 80.2% 83.3%  
     Current drinker, ≥3 drinks/day 9.8% 6.7%  
Body mass index (BMI), kg/m2 28.6 ± 0.20 29.2 ± 0.35 <0.0001
Serum total cholesterol, % 229.1 ± 1.19 238.1 ± 2.54 <0.0001
Hypertension, % 39.7% 54.6%  
Systolic blood pressure, mm Hg 128.2 ± 0.67 133.4 ± 1.14 <0.0001
Diastolic blood pressure, mm Hg 78.27 ± 0.37 78.94 ± 0.63 <0.0001
†p-value estimated by analysis of variance or chi-square test as appropriate
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Table 4.2. Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident CKD
Serum sVCAM-1 quartiles* 
(n=1045) No. at risk
Cases
(n=269)
Unadjusted hazards ratio (95% 
confidence interval) 
Multivariable-adjusted
hazards ratio (95% confidence interval)‡
Quartile 1  260 62 1 (referent category) 1 (referent category)
Quartile 2  262 52 0.87 (0.60, 1.25) 0.82 (0.55, 1.23)
Quartile 3  262 75 1.29 (0.92, 1.81) 1.15 (0.79, 1.67)
Quartile 4  261 80 1.53 (1.10, 2.13) 1.14 (0.77, 1.68)
     p-trend   0.0021 0.2662
Log-transformed sVCAM-1   2.23 (1.41, 3.53) 1.54 (0.91, 2.60)
     
Serum sICAM-1 quartiles† 
(n=1045)     
Quartile 1  262 60 1 (referent category) 1 (referent category)
Quartile 2  260 69 1.16 (0.82, 1.64) 1.03 (0.70, 1.51)
Quartile 3  261 73 1.32 (0.94, 1.86) 1.05 (0.72, 1.54)
Quartile 4  262 67 1.18 (0.83, 1.67) 1.04 (0.69, 1.55)
     p-trend   0.2707 0.8466
Log-tranformed sICAM-1   1.54 (1.00, 2.38) 1.33 (0.79, 2.25)
     
*sVCAM Quartiles: Quartile 1 (0-638.8 (ng/ml)), Quartile 2 (638.9-755.2 ng/ml), Quartile 3 (755.3-878.7), Quartile 4 ( > 878.7 ng/ml)
†sICAM-1:  soluble intercellular adhesión molecule-1; sICAM Quartiles: Quartile 1 (0-234.2 (ng/ml)), Quartile 2 (234.3-278.4 ng/ml), Quartile 3 (278.5-
324.6), Quartile 4 ( > 342.6 ng/ml) 
‡Adjusted for age (years), education categories (<high school, high school, >high school), smoking (never, former, current), alcohol intake (never, former, 
current), body mass index (kg/m2), hypertension (absent, present) and serum cholesterol (%) 
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Table 4.3. Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident CKD stratified by gender
 Men Women
Serum sVCAM-1 quartiles* (n=1045) 
Multivariable-adjusted
hazards ratio (95% confidence interval) ‡ 
Multivariable-adjusted
hazards ratio (95% confidence interval) ‡
Quartile 1  1 (referent category) 1 (referent category)
Quartile 2  0.64 (0.35, 1.19) 0.97 (0.60, 1.56)
Quartile 3  1.33 (0.77, 2.30) 0.94 (0.59, 1.50)
Quartile 4  0.91 (0.49, 1.68) 1.20 (0.76, 1.89)
     p-trend 0.6041 0.4393
   
Serum sICAM-1 quartiles† (n=1045)   
Quartile 1  1 (referent category) 1 (referent category)
Quartile 2  1.15 (0.65, 2.04) 0.96 (0.61, 1.50)
Quartile 3  1.28 (0.72, 2.27) 0.94 (0.61, 1.46)
Quartile 4  1.26 (0.69, 2.30) 0.90 (0.56, 1.45)
     p-trend 0.4112 0.6593
   
* sVCAM-1: soluable vascular cell adhesion molecule-1; sVCAM Quartiles: Quartile 1 (0-638.8 (ng/ml)), Quartile 2 (638.9-755.2 ng/ml), 
Quartile 3 (755.3-878.7), Quartile 4 ( > 878.7 ng/ml) 
†sICAM-1: soluable intercellular adhesión molecule-1; sICAM Quartiles: Quartile 1 (0-234.2 (ng/ml)), Quartile 2 (234.3-278.4 ng/ml), 
Quartile 3 (278.5-324.6), Quartile 4 ( > 342.6 ng/ml) 
‡Adjusted for age (years), education categories (<high school, high school, >high school), smoking (never, former, current), alcohol intake 
(never, former, current), body mass index (kg/m2), hypertension (absent, present) and serum cholesterol (%)
 
 
  
 54 
 
Table 4. 4. Association between increasing serum levels of sVCAM-1 and sICAM-1 and incident CKD stratified by hypertension status
 
No Hypertension
 (n=590)
Hypertension
(n=455)
Serum sVCAM-1 quartiles*(n=1045) 
Multivariable-adjusted
hazards ratio (95% confidence interval) ‡ 
Multivariable-adjusted
hazards ratio (95% confidence interval) ‡
Quartile 1  1 (referent category) 1 (referent category)
Quartile 2  0.73 (0.41, 1.30) 0.92 (0.52, 1.62)
Quartile 3  1.15 (0.68, 1.96) 1.12 (0.64, 1.94)
Quartile 4  1.10 (0.62, 1.95) 1.83 (0.69, 2.04)
     p-trend 0.4589 0.4198
   
Serum sICAM-1 quartiles† (n=1045)   
Quartile 1  1 (referent category) 1 (referent category)
Quartile 2  1.39 (0.81, 2.39) 0.79 (0.46, 1.36)
Quartile 3  0.82 (0.45, 1.45) 1.21 (0.72, 2.03)
Quartile 4  1.29 (0.72, 2.32) 0.85 (0.48, 1.51)
     p-trend 0.7463 0.9415
   
* sVCAM-1: soluable vascular cell adhesion molecule-1; sVCAM Quartiles: Quartile 1 (0-638.8 (ng/ml)), Quartile 2 (638.9-755.2 ng/ml), 
Quartile 3 (755.3-878.7), Quartile 4 ( > 878.7 ng/ml) 
†sICAM-1: soluable intercellular adhesión molecule-1; sICAM Quartiles: Quartile 1 (0-234.2 (ng/ml)), Quartile 2 (234.3-278.4 ng/ml), 
Quartile 3 (278.5-324.6), Quartile 4 ( > 342.6 ng/ml) 
‡Adjusted for age (years), education categories (<high school, high school, >high school), smoking (never, former, current), alcohol intake 
(never, former, current), body mass index (kg/m2), and serum cholesterol (%)
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5.1 INTRODUCTION 
Cardiovascular disease is the leading cause of mortality in the United States.149   
Endothelial dysfunction is a key pathophysiological process involved in the development of 
cardiovascular disease.76 Soluble adhesion molecules, including serum levels of soluble vascular 
cell adhesion molecule-1 (sVCAM) and intercellular adhesion molecule -1 (sICAM) have been 
used as reliable markers of endothelial dysfunction in epidemiological studies.150  sVCAM-1 and 
sICAM-1 levels have shown to be associated with cardiovascular disease in the general 
population114,151 and have also been shown to be associated with cardiovascular mortality in 
subjects undergoing hemodialysis91, and those with coronary heart disease92 and rheumatoid 
arthritis93.   However, to our knowledge, no epidemiological study has examined the putative 
relationship between soluble adhesion molecules and cardiovascular mortality in the general 
population. Therefore, we examined serum levels of sVCAM-1 and sICAM-1 in relationship to 
cardiovascular mortality in a population-based sample of adults from Wisconsin. 
 57 
 
5.2 METHODS 
5.2.1 Population 
 
The current study is based on data from the Beaver Dam Eye study, a population-based 
cohort study in Wisconsin originally aimed at studying age-related eye diseases. The methods 
used to identify and describe the Beaver Dam population have appeared in previous reports.152,153 
In brief, a private census of the population of Beaver Dam, Wisconsin, was performed from 
September 1987 to May 1988 to identify all residents in the city or township of Beaver Dam who 
were 43-84 years of age. Of the 5,924 eligible individuals (98% Caucasians), 4,926 (83.1%) 
participated in the baseline examination between March 1, 1988 and September 14, 1990. 
Comparisons between participants and nonparticipants at the time of the baseline examination 
have appeared elsewhere153.  
The baseline examination was followed by four follow-up examinations every 5 years. 
Written informed consent was obtained from each subject at each examination. The study was 
approved by the Human Subjects Committee of the University of Wisconsin School of Medicine 
and Public Health, Madison, WI.   Serum levels of sVCAM-1 and sICAM -1 were measured on a 
random sample of the baseline cohort (n=1793) as part of an ancillary study examining risk 
factors for kidney disease.  
For the longitudinal analyses with sVCAM-1 and sICAM-1 as the main exposure, out of 
1793 individuals with available sVCAM-1 and sICAM-1 measurements, we excluded subjects 
with missing information on covariates included in the multivariable model (n=38) and those 
who had a history of prevalent cardiovascular disease (n=247). This resulted in n=1508 
cardiovascular disease-free individuals with complete covariate information to form the at-risk 
study population.  
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5.2.2 Exposure ascertainment 
The baseline and follow-up examinations included measurement of weight, height, 
systolic and diastolic blood pressure by trained observers and administering a standardized 
questionnaire that collected information regarding participants’ demographic characteristics, 
details regarding cigarette smoking, alcohol intake, medical histories and medications taken, 
including physician-diagnosed diabetes, hypertension or cardiovascular disease (CVD). Non-
fasting blood specimens were obtained for measurement of plasma glucose, glycosylated 
hemoglobin, serum total cholesterol and high density lipoprotein (HDL) cholesterol.  
Age was defined as the participants’ age at the time of the baseline examination. 
Education was categorized as less than high school, high school, or beyond high school. Body 
mass index (BMI) was defined as participants’ weight in kilograms divided by their height in 
meters squared. Hypertension was defined as a systolic blood pressure of 140 mmHg or higher, 
and/or a diastolic blood pressure 90 mmHg or higher, and/or the combination of self-reported 
hypertension diagnosis by a physician and use of antihypertensive medications.  Diabetes was 
defined as being treated with insulin, oral hypoglycemic agents, or were newly classified as 
having diabetes based on the glycosylated hemoglobin value that was ≥ 6.5%, consistent with 
recent American Diabetes Association guidelines104 Chronic kidney disease was defined as 
having chronic kidney disease were defined as having an estimated glomerular filtration rate 
(GFR) of <60 ml/min per m2, estimated from serum creatinine employing the re-expressed 
Modification of Diet in Renal Diseases (MDRD) study equation.117 
At cohort examinations, blood samples were collected in three 10-mL liquid EDTA blood 
tubes, placed on ice packs, stored in Styrofoam containers until they were centrifuged and 
aliquoted for storage in freezers at –800C until the time of laboratory analysis. Quality control 
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samples were routinely frozen with study participant samples. Baseline frozen plasma samples 
were randomly ordered (to further reduce systematic bias and inter assay variation) and thawed 
and batch-analyzed for markers of endothelial function (sVCAM-1, sICAM-1). 
sVCAM-1 was measured in plasma or serum using the quantitative sandwich enzyme 
technique of the enzyme-linked immunosorbent assay (ELISA) Parameter kit from R & D 
Systems (Minneapolis, MN).  The intensity of the color was measured on a SpectraMax 
spectrophotometer (Molecular Devices, Sunnyvale, California).  The inter-assay CV range was 
8.9-10.2%.. 
sICAM-1 (was measured in plasma using the quantitative sandwich enzyme technique of 
the enzyme-linked immunosorbent assay (ELISA) Parameter kit from R & D Systems 
(Minneapolis, MN).  The intensity of the color was measured on a SpectraMax 
spectrophotometer (Molecular Devices, Sunnyvale, California).  The inter-assay CV range was 
6.0-10.1%. 
 
5.2.3  Outcome of Interest: Cardiovascular Mortality 
We ascertained mortality between the baseline examination and December 31, 2002. 
Mortality surveillance of the cohort consisted of reviews of daily newspaper obituaries, regular 
contact with study participants and their relatives, designated contact persons, or physicians. 
Deaths were confirmed with death certificate data from annual requests made to the Wisconsin 
Center for Health Statistics, Section of Vital Statistics. The names of persons who have moved 
out of Wisconsin and those who had been lost to follow-up or were suspected to have died were 
submitted for matching against Wisconsin death records and the National Death Index. For each 
match made, a copy of the death certificate was secured from the appropriate state. Only deaths 
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that have been confirmed by death certificates were included in the definition of mortality. Death 
certificates were collected and coded by trained nosologists using the International Classification 
of Diseases, Ninth Revision (ICD-9). We have estimated that all the deaths in the cohort have 
been identified by our surveillance methods. Cardiovascular mortality was identified using ICD 
9 codes 401-459, including death due to coronary heart disease and stroke as the underlying 
cause of death. 
 
5.2.4 Statistical methods 
We were interested in the association between serum levels of sVCAM-1 and sICAM-1 
and cardiovascular mortality. We categorized sVCAM-1 and sICAM-1 into quartiles for the 
main analysis. We also analyzed these markers as continuous variables after logarithmic 
transformation due to their skewed distribution.  
We used chi-square test and analysis of variance to compare the relationship of selected 
baseline characteristics to increasing categories of sVCAM-1. We used multivariable Cox 
proportional hazard regression models to determine the hazard ratio (HR) and 95 percent 
confidence interval (CI) of 15-year cardiovascular mortality, controlling simultaneously for 
potential confounders. We used two nested Cox proportional hazard regression models: an 
unadjusted model and a multivariable-adjusted model, adjusted for age (years), education 
categories (<high school, high school, >high school), smoking (never, former, current), alcohol 
intake (never, former, current), body mass index (kg/m2), hypertension (absent, present), diabetes 
(absent, present), serum cholesterol (%) and chronic kidney disease (yes, no).  To examine the 
consistency of the association between sVCAM-1 and sICAM-1 levels and cardiovascular 
mortality, we performed subgroup analyses by gender (men, women), diabetes mellitus (absent, 
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present), hypertension (absent, present) and chronic kidney disease (absent, present). Finally, we 
evaluated effect modification by including cross-product multiplicative interaction terms in 
regression models (alpha=0.l0 for testing interaction). 
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5.3 RESULTS 
Among 1508 study participants included in the current analysis, there were 639 men and 
869 women. Overall, 212 subjects (14%) died of cardiovascular causes, including 96 men and 
116 women.  
Table 5.1 presents the characteristics of the study population by increasing serum 
sVCAM-1 levels at baseline. Those who had higher serum sVCAM-1 levels were more likely to 
be older, educated below high school, never smokers, never drinkers, have lower cholesterol 
levels and diastolic blood pressures.  
Table 5.2 presents the association between increasing categories of serum sVCAM-1, 
sICAM-1 and cardiovascular mortality. The multivariable model for sVCAM-1 showed a 
positive association between increasing serum sVCAM-1 levels and cardiovascular mortality, 
although the model evaluating linear trend in this association was just shy of statistical 
significance (p-trend=0.0904). The multivariable model for sICAM-1 showed a positive 
association between increasing serum sICAM-1 levels and cardiovascular mortality and the 
model evaluating linear trend in this association was statistically significant (p-trend=0.0097).  
Table 5.3 presents the associations between increasing categories of serum sVCAM-1, 
sICAM-1 and cardiovascular mortality, stratified by gender, diabetes, hypertension, chronic 
kidney disease and BMI status. The multivariable model for sVCAM-1 showed a stronger 
association with cardiovascular mortality in women, those with diabetes, hypertension, chronic 
kidney disease and those with normal BMI. The multivariable model for sICAM-1 showed a 
stronger association with cardiovascular mortality in women, in those without diabetes and 
hypertension and in those with chronic kidney disease and normal BMI. Formal statistical tests 
for interaction were not significant (all p-interactions>0.10). 
 63 
 
Supplementary analyses that additionally adjusted for high sensitivity c-reactive in the 
multivariable model as a marker of inflammation did not alter the magnitude of results.  
Compared to the lowest quartiles of sVCAM-1 (referent) and sICAM-1 (referent), the 
multivariable odds ratio (95% confidence interval) of cardiovascular mortality for sVCAM-1 
quartiles 1-4 respectively were 1.34 (0.80, 2.24), 1.26 (0.77,  2.08),  and 1.53 (0.94, 2.51))  and for 
sICAM-1 quartiles 1-4 respectively were 1.39 (0.89, 2.17), 1.42 (0.92, 2.20) and 1.73 (1.13, 2.76). 
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5.4 DISUCSSION 
In a population-based sample of adults from Wisconsin, increasing serum levels of 
sVCAM-1 and sICAM-1 were found to be positively associated with cardiovascular mortality. 
These associations were independent of age, gender smoking, alcohol intake, education, 
hypertension, diabetes, chronic kidney disease, body mass index and total cholesterol. In 
subgroup analyses, the association between sVCAM-1 and sICAM-1 levels and cardiovascular 
mortality appeared to be relatively consistently present among those with and without diabetes, 
hypertension, chronic kidney disease and obesity. 
Serum levels of sICAM-1 and sVCAM-1 have been used in epidemiological research 
before as reliable markers of endothelial dysfunction.150 Previous studies have reported that 
markers of endothelial dysfunction are associated with increased risk cardiovascular 
disease76,114,151 and cardiovascular mortality in ill subpopulations.91-93 However, since these 
endothelial dysfunction markers are also known to be elevated secondary to these chronic 
diseases (or as a result of treatments for these diseases, such as hemodialysis for kidney disease), 
results from such studies of patient cohorts may not reflect disease processes occurring in the 
general population. In the current study, we examined, to our knowledge for the first time, the 
association between increasing levels of markers of endothelial dysfunction in serum and their 
relationship to cardiovascular mortality in a general population sample. Subsequently, we found 
that markers of endothelial dysfunction are positively related to cardiovascular mortality. This 
finding is consistent with a previous report of an overall association of markers of endothelial 
dysfunction and incident cardiovascular disease in the Atherosclerosis Risk in Communities 
Study.114   
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Because there are several cardiovascular risk factors that are associated with an increase 
in endothelial dysfunction, including gender154,155, diabetes,156,157 hypertension,157,158chronic 
kidney disease159,160 and obesity161,162, we adjusted and stratified by these risk factors to test the 
independent association between these markers of endothelial dysfunction and cardiovascular 
mortality.  We found that the association between endothelial dysfunction and cardiovascular 
mortality was attenuated, but still present, even after multivariable adjustment for confounders. 
Also, there was no statistically significant difference in the association of markers of endothelial 
dysfunction to cardiovascular mortality in subgroup analyses by gender, diabetes, hypertension, 
chronic kidney disease and BMI. 
 The intact, healthy endothelium secretes various cardio-protective substances including 
nitric oxide, which diffuses to surrounding tissues and cells, relaxing smooth-muscle cells and 
preventing platelet adhesion and aggregation, preventing expression of adhesion molecules, 
leukocyte adhesion and migration into the arterial wall and arterial smooth muscle cell 
proliferation77.  Conversely, early stages of endothelial dysfunction is characterized by increased 
formation of reactive oxygen species and increased expression of adhesion molecules such as 
sVCAM-1 and sICAM-1, which can react with NO forming peroxynitrate78, reducing NO 
bioavailability, which over the long run may be involved in increased risk of cardiovascular 
disease79. Results from our study, which show a positive association between increased 
circulating levels of endothelial adhesion molecules and cardiovascular mortality in a general 
population sample, are therefore consistent with these proposed biological mechanisms and 
indirectly suggest that there may be a role for treating endothelial dysfunction to prevent 
cardiovascular mortality. 
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Strengths of this study include its population-based sample, high participation rate, use of 
standardized protocols for exposure and outcome measurement, complete mortality surveillance 
and the availability of specific markers of endothelial dysfunction, including sVCAM-1 and 
sICAM-1 levels. Also, misclassification of cardiovascular mortality may have biased our results. 
Study limitation include selective survival, high variability and the generalizability of our study 
to other populations as this sample is a 99% white and is greater than or equal to 43 years of age. 
In conclusion, in a population-based sample of Wisconsin adults, we found that 
increasing serum levels of sVCAM-1 and sICAM-1 levels were positively associated with 
cardiovascular mortality, independent of age smoking status, alcohol intake, education, 
hypertension, diabetes, chronic kidney disease, BMI, and total cholesterol levels.  
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5.5 TABLES 
  
Table 5.1. Baseline characteristics by vascular cell adhesion molecule 1 (sVCAM -1) quartiles 
 Serum sVCAM-1 quartiles*  
Characteristics Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value†
Age, years 55.5 ± 0.52 58.7 ± 0.52 61.0 ± 0.52 67.0 ± 0.52 <0.0001
Females, % 55.2% 54.6% 57.8% 62.9% 0.0878
Education, %      
     Below high school 16.7% 21.2% 24.4% 37.9% <0.0001
     High school 46.4% 47.8% 47.8% 39.0%  
     Above high school 36.9% 31.0% 27.8% 23.1%  
Smoking, %     0.0003
     Never 41.4% 43.2% 44.8% 54.4%  
     Former 32.1% 34.0% 34.5% 32.3%  
     Current 26.5% 22.8% 20.7% 13.3%  
Alcohol intake categories, %     <0.0001
     Never 1.0% 2.1% 3.5% 5.8%  
     Former 8.8% 8.7% 9.8% 13.3%  
     Current drinker, <2 drinks/day 77.2% 79.6% 80.3% 76.4%  
     Current drinker, ≥3 drinks/day 13.0% 9.6% 6.4% 4.5%  
Body mass index (BMI), kg/m2 28.7 ± 0.29 28.3 ± 0.29 29.2 ± 0.29 29.1 ± 0.29 <0.0001
Serum total cholesterol, % 242.6 ± 2.26 235.6 ± 2.26 230.2 ± 2.26 226.9 ± 2.26 <0.0001
Hypertension, % 39.8% 46.4% 43.5% 61.5% <0.0001
Systolic blood pressure, mm Hg 128.4 ± 1.01 130.2 ± 1.01 130.0 ± 1.01 137.7 ±1.01 <0.0001
Diastolic blood pressure, mm Hg 78.7 ± 0.56 78.1 ± 0.56 77.4 ± 0.56 77.2 ± 0.56 <0.0001
*sVCAM-1 Quartiles: Quartile 1 (0-651.6 (ng/ml)), Quartile 2 (651.7-768.2 ng/ml), Quartile 3 (768.3-918.8), Quartile 4 ( >918.8 ng/ml)
†p-value estimated by analysis of variance or chi-square test as appropriate
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Table 5.2. Association between increasing serum levels of sVCAM-1  and sICAM-1 and cardiovascular mortality
Serum sVCAM-1 quartiles* 
(n=1508) No. at risk
Mortality 
cases 
(n=212)
Unadjusted hazards ratio (95% 
confidence interval) 
Multivariable-adjusted 
hazards ratio (95% confidence interval) ‡
Quartile 1  377 24 1 (referent category) 1 (referent category)
Quartile 2  377 39 1.68 (1.01, 2.79) 1.31 (0.78, 2.19)
Quartile 3  377 54 2.40 (1.48, 3.88) 1.22 (0.74,  2.01)
Quartile 4  377 95 4.90 (3.07, 7.52) 1.56 (0.95, 2.54)
     p-trend   < 0.0001 0.0904
     
Serum sICAM-1 quartiles† 
(n=1504)     
Quartile 1  377 31 1 (referent category) 1 (referent category)
Quartile 2  378 52 1.69 (1.09, 2.63) 1.45 (0.93, 2.26)
Quartile 3  372 59 2.01 (1.31, 3.10) 1.47 (0.95, 2.27)
Quartile 4  377 69 2.47 (1.62, 3.76) 1.79 (1.17, 2.76)
     p-trend   < 0.0001 0.0097
     
*sVCAM-1 Quartiles: Quartile 1 (0-651.6 (ng/ml)), Quartile 2 (651.7-768.2 ng/ml), Quartile 3 (768.3-918.8), Quartile 4 ( >918.8 ng/ml)
†sICAM-1 Quartiles: Quartile 1 (0-237.2 (ng/ml)), Quartile 2 (237.3-281.2 ng/ml), Quartile 3 (281.3-330.8), Quartile 4 ( > 330.8 ng/ml) 
‡Adjusted for age (years), education categories (<high school, high school, >high school), smoking (never, former, current), alcohol intake 
(never, former, current), body mass index (kg/m2), hypertension (absent, present), diabetes (absent, present), serum cholesterol (%), 
chronic kidney disease (yes, no)   
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Table 5.3. Association by sICAM-1 and  sVCAM-1 and cardiovascular  mortality in selected subgroups*
Categories 
Sample 
size 
sVCAM-1
The multivariable-adjusted hazards ratio† (95% 
confidence interval) for one standards deviation 
increase‡
sICAM-1
The multivariable-adjusted hazards ratio† (95% 
confidence interval) for one standards deviation 
increase‡
Gender    
   Female 869 1.51 (1.18, 1.95) 1.54 (1.18, 2.01)
   Men 639 1.25 (1.00, 1.56) 1.13 (0.92, 1.35)
Body Mass Index    
   Normal BMI 361 1.59 (1.11, 2.27) 1.60 (1.09, 2.32)
   Overweight/Obese 1144 1.34 (1.08, 1.67) 1.14 (0.96, 1.36)
Diabetes mellitus     
   Absent  1020 1.34 (1.10, 1.62) 1.36 (1.13, 1.64)
   Present 488 1.68 (1.09, 2.60) 1.21 (0.93, 1.58)
Hypertension        
   Absent 560 1.28 (0.95, 1.73) 1.88 (1.25, 2.83)
   Present 948 1.39 (1.11, 1.73) 1.08 (0.90, 1.30)
Chronic kidney disease    
   Absent 1240 1.35 (1.06, 1.70) 1.18 (0.98, 1.43)
   Present 268 1.41 (1.12, 1.96) 1.37 (1.08, 1.75)
*All p-interactions > 0.10 
† Adjusted for age (years), gender (male, female), education categories (<high school, high school, >high school), smoking (never, former, 
current), alcohol intake (never, former, current), body mass index (kg/m2), hypertension (absent, present), diabetes (absent, present), serum 
cholesterol (%), chronic kidney disease (yes, no)   
‡ one standard deviation sVCAM-1 = 288.4 units; one standard deviation of sICAM-1 = 98.5 units
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Discussion  
 71 
 
6.1 SUMMARY OF KEY FINDINGS 
 In an attempt to resolve the current gaps in literature (as mentioned in the Introduction 
section), we conducted four related studies in a large population-based cohort study in Beaver 
Dam, Wisconsin, to examine the role of serum markers of endothelial dysfunction on various 
common  metabolic and cardiovascular outcomes in humans, including diabetes mellitus, 
hypertension, CKD, and cardiovascular mortality.  We found that markers of endothelial 
dysfunction, including serum sVCAM-1 and sICAM-1, were positively associated with the risk 
of developing diabetes, hypertension, and cardiovascular mortality, but not with CKD (see a 
summary of these findings in Table 6.1.). Further, in subgroup analyses, we found that the 
association between these endothelial dysfunction markers and diabetes mellitus was present 
mainly in men, but not women. All other associations were present similarly in men and women. 
Based on these findings, we propose a conceptual model that markers of endothelial dysfunction 
are related to cardiovascular mortality probably through its relation to diabetes mellitus and 
hypertension, but not to CKD (see Figure 6.1.). 
 
6.2 ENDOTHELIAL DYSFUNCTION AND DIABETES MELLITUS (MANUSCRIPT 
1/CHAPTER 2) 
The findings from our first manuscript of an association between sVCAM-1 and sICAM-
1 and diabetes mellitus in men are consistent with a previous study by Thorand et al. showing 
serum  endothelial dysfunction marker levels to be associated with increased risk of type 2 
diabetes in men and not in women.84  Also, another study showed that when measuring 
endothelial function as reactive hyperemia by peripheral arterial tonometry, endothelial 
dysfunction was associated with diabetes and hyperglycemia in adolescent males but not 
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adolescent females.83 It is biologically plausible that endothelial dysfunction is related to incident 
diabetes mellitus through its relation to mechanisms such as hyperglycemia, insulin resistance, 
excess free fatty acids release and compensatory hyperinsulinemia.105  Similarly, several 
plausible mechanisms can be postulated to explain the lack of association between endothelial 
dysfunction and diabetes mellitus in women in the current study, including that female hormones 
are cardioprotective and therefore to some extent may mitigate any adverse effect of endothelial 
dysfunction.106 However, there is a need for more studies in this topic to clarify the modifying 
effect of female gender in the association between endothelial dysfunction and diabetes. 
 
6.3 ENDOTHELIAL DYSFUNCTION AND HYPERTENSION (MANUSCRIPT 
2/CHAPTER 3) 
The findings from our second manuscript of an association between sVCAM-1 and 
hypertension is consistent with one previous prospective epidemiological study examining the 
relationship between biomarkers of endothelial dysfunction and hypertension in those with type 
1 diabetes86 and another cross-sectional study in the general population conducted in China.88 
The observed association between endothelial dysfunction and hypertension may be due to 
endothelial damage and related dysfunction impairing the vasodilator mechanism of 
endothelium-derived relaxing factor (nitric oxide), subsequently causing elevated blood 
pressure34. Endothelial dysfunction may also be related to other mechanisms involved in the 
development of hypertension, including insulin resistance,64 systemic inflammation65 and 
hyperuricemia.66 However, in our study, we also found that even though sVCAM-1 was 
positively related to incident hypertension, sICAM-1 was not. While the reasons for these 
differing associations between sVCAM-1 and sICAM-1 are not entirely clear, there are several 
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hypotheses that can be postulated to explain this finding. It is possible that even though these 
adhesion molecules are similar in structure they have different functions. For example, recent 
animal studies have shown that VCAM-1, and not ICAM-1, plays a major role in the initiation of 
atherosclerosis125, and others that have reported differential expression patterns for these 
adhesion molecules in the vascular tree with VCAM-1 being expressed more in atherosclerotic 
lesions whereas ICAM-1 expression extending into uninvolved aorta and lesion protected 
regions.126 However, there is a need for more human studies to validate or refute our findings. 
 
6.4 ENDOTHELIAL DYSFUNCTION AND CKD (MANUSCRIPT 3/CHAPTER 4) 
The findings from our third manuscript showed that sVCAM-1 and sICAM-1 are not 
independently related to incident CKD. We originally initiated this study because there was 
strong biologically plausible data from animal studies to suggest that endothelial dysfunction 
may have a role in the development of kidney disease. Janssen et al.145  reported that ICAM-1 
knockout mice developed significantly less severe experimentally induced nephrotoxic nephritis 
and glomerular crescents compared to control mice. Similarly, Kawasaki et al. showed that 
injection of antibodies against ICAM-1 prevented glomerular injury in experimental crescentic 
glomerular nephritis146. The importance of our study is that to our knowledge, this is the first 
prospective study in humans to examine the association between endothelial dysfunction and the 
development of renal disease using circulating levels of cellular adhesion molecules.  Since 
markers of endothelial dysfunction are known to be elevated secondarily in kidney disease89,90 
and also as a result of hemodialysis163, the first line of treatment for late stages of kidney disease, 
it is critically important to conduct a prospective study to investigate this association so as to 
clarify the temporal nature of any associations detected. In our study, we found that even though 
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there was a moderate positive association between sVCAM-1 and sICAM-1 and incident CKD in 
the unadjusted model, the association was no longer present after adjusting for lifestyle and 
medical risk factors. Therefore, our findings indirectly suggest that treatment/control of lifestyle 
and medical risk factors for CKD such as higher BMI, diabetes, and hypertension should 
continue to be the mainstay of treatment for CKD. 
 
6.5 ENDOTHELIAL DYSFUNCTION AND CARDIOVASCULAR MORTALITY 
(MANUSCRIPT 4/CHAPTER 5) 
The findings from our fourth manuscript showed that sVCAM-1 and sICAM-1 levels are 
positively associated with cardiovascular mortality. Previous studies have reported that markers 
of endothelial dysfunction are associated with increased risk of developing cardiovascular 
disease76,114,151 and cardiovascular mortality in ill subpopulations.91-93 However, since these 
endothelial dysfunction markers are also known to be elevated secondary to these chronic 
diseases89,90,163 (or as a result of treatments for these diseases), results from such studies of 
patient cohorts may not reflect disease processes occurring in the general population. In the 
current study, we found that markers of endothelial dysfunction are positively related to 
cardiovascular mortality. Our finding is consistent with a previous report of an overall 
association of markers of endothelial dysfunction and incident cardiovascular disease in the 
Atherosclerosis Risk in Communities Study.114   
 
6.6 SIGNIFICANCE OF THE STUDY 
 After exploring markers of endothelial dysfunction in relation to diabetes, hypertension, 
CKD and cardiovascular mortality, endothelial dysfunction was shown to play a major role in all 
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chronic disease outcomes under study except CKD.  Clinically, these results suggest that treating 
endothelial dysfunction may prevent diabetes, hypertension and cardiovascular mortality in 
patients and in populations.   
 
6.7 STRENGTHS AND LIMITATIONS 
Since from an epidemiological pint of view, temporality is a major tenant of  a truly 
causal association, one important advantage of our study is the longitudinal nature of the Beaver 
Dam Eye Study cohort dataset. The availability of long-standing prospective data on a 
representative general population  sample allowed us to elucidate the temporal nature of the 
association between markers of endothelial dysfunction and the various cardiometabolic 
outcomes we studied. This is especially important in the case of CKD where markers of 
endothelial dysfunction are known to be elevated secondarily in later stages of kidney disease89,90 
and also as a result of hemodialysis, a main stay of advanced CKD and end-stage renal disease 
treatment.163  Another advantage of our study is the availability of a truly population-based 
sample (as opposed to clinical patient populations). This is especially important in our study on 
cardiovascular morality as markers of endothelial dysfunction are known to be elevated  
secondarily in various disease states, such as those with rheumatoid arthritis and CKD.163 Other 
strengths of the Beaver Dam Eye Study cohort include its high participation rate and use of 
standardized protocols for exposure and outcome measurement and the availability of specific 
serum markers of endothelial dysfunction, including sVCAM-1 and sICAM-1 levels. Our results 
of positive and null associations between markers of endothelial dysfunction and incident 
chronic disease outcomes and cardiovascular mortality possess strong internal validity as we 
adjusted for and stratified by known confounders. 
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 A main study limitation is the limited generalizability of our study to other populations 
as our study sample is a 99% white sample. Also since we used serum markers of endothelial 
dysfunction, there is some potential for exposure misclassification which could under or 
overestimate our results. Finally, as in any longitudinal study, it is possible that there are biases 
related to selective survival (e.g. sick people dying more than healthy individuals), time-varying 
confounding (e.g. a smoker at baseline may quit smoking , whereas a nonsmoker may start 
smoking at a later date—which may affect their endothelial dysfunction marker level as well as 
risk of diseases). Assuming that these changes are randomly distributed across levels of baseline 
endothelial dysfunction marker, we believe that any misclassification is likely to be 
nondifferential and likely to underestimate the true association. 
 
6.8 FUTURE RESEARCH 
 To build upon our novel findings, we suggest that future investigations should include 
assessing these relationships in ethnic diverse cohorts to assess whether or not the relationships 
differ by ethnicity.  For example, it is possible that some of the observed associations—
especially the association between endothelial dysfunction and hypertension—may vary by 
race/ethnicity and that the difference in our findings to that in the literature may be explained by 
such underlying racial/ethnic differences. Thus there is a need for future studies with adequate 
sample sizes of various race/ethnicities to enable valid cross-ethnicity comparisons. Second, our 
study measured these novel markers of endothelial dysfunction only in the baseline Beaver Dam 
Eye Study cohort study samples. Since it is well known that levels of these markers may change 
over time due to changing lifestyle, environmental, and biological factors, as a future research 
topic, it is important to study the time varying effect of these markers of endothelial dysfunction 
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by measuring them at multiple follow-up occasions in the same cohort.  Lastly, it is important to 
study the genetic factors that may predispose individuals to increased endothelial dysfunction in 
response to lifestyle and environmental risk factors.   
 
6.9 CONCLUSION   
In summary, markers of endothelial dysfunction, including serum levels of sVCAM-1 
and sICAM-1 were found to be associated with increased risk of developing diabetes mellitus in 
men, and with hypertension and cardiovascular mortality in both men and women.  However, 
these markers of endothelial dysfunction were not found to be associated with the risk of 
developing CKD, independent of known lifestyle and medical risk factors. Consequently, the 
significance of our findings is that we are able to clarify the relationships between endothelial 
dysfunction and various risk factors/mediators of cardiovascular mortality by examining them in 
a single, large, population-based dataset. Our results point to the conclusion that endothelial 
dysfunction may be related to cardiovascular mortality through its relation to diabetes mellitus 
and hypertension but not to CKD. 
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6.10 TABLES AND FIGURES 
 
Table 6.1. Summary of Associations between Markers of Endothelial Dysfunction and Outcomes of Interest 
 sVCAM-1  sICAM-1 
 Overall Men Women  Overall Men Women 
Diabetes Mellitus + + -  + + - 
Hypertension + + +  - - - 
Chronic Kidney Disease - - -  - - - 
Cardiovascular Mortality + - +  + - - 
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Figure 6. 1. The Mediation of Endothelial Dysfunction and Cardiovascular Mortality by Gender 
Based on results from the four studies, we propose that endothelial dysfunction is related to 
cardiovascular mortality through its relation to diabetes and hypertension in men, and through it 
relation to hypertension in women, since endothelial dysfunction was not found to be related to 
diabetes in them.  Even though it is known that CKD is a risk factor for cardiovascular mortality, we 
propose that CKD is not involved in the causal association between endothelial dysfunction and 
cardiovascular mortality as we did not find an association between endothelial dysfunction and CKD. 
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